Company Quick10K Filing
Fortive
Price69.50 EPS8
Shares340 P/E9
MCap23,623 P/FCF29
Net Debt4,955 EBIT2,860
TEV28,578 TEV/EBIT10
TTM 2019-09-27, in MM, except price, ratios
10-K 2020-12-31 Filed 2021-02-26
10-Q 2020-09-25 Filed 2020-10-27
10-Q 2020-06-26 Filed 2020-07-28
10-Q 2020-03-27 Filed 2020-04-30
10-K 2019-12-31 Filed 2020-02-27
10-Q 2019-09-27 Filed 2019-10-25
10-Q 2019-06-28 Filed 2019-07-25
10-Q 2019-03-29 Filed 2019-04-25
10-K 2018-12-31 Filed 2019-02-28
10-Q 2018-09-28 Filed 2018-10-25
10-Q 2018-06-29 Filed 2018-07-26
10-Q 2018-03-30 Filed 2018-04-26
10-K 2017-12-31 Filed 2018-02-28
10-Q 2017-09-29 Filed 2017-10-26
10-Q 2017-06-30 Filed 2017-07-27
10-Q 2017-03-31 Filed 2017-04-27
10-K 2016-12-31 Filed 2017-02-28
10-Q 2016-09-30 Filed 2016-10-27
10-Q 2016-07-01 Filed 2016-08-02
8-K 2021-02-04
8-K 2021-01-19
8-K 2021-01-06
8-K 2020-12-06
8-K 2020-11-10
8-K 2020-10-27
8-K 2020-10-08
8-K 2020-10-05
8-K 2020-09-29
8-K 2020-09-09
8-K 2020-09-09
8-K 2020-08-06
8-K 2020-07-28
8-K 2020-06-02
8-K 2020-04-24
8-K 2020-02-25
8-K 2020-02-06
8-K 2020-01-16
8-K 2019-10-24
8-K 2019-10-21
8-K 2019-10-03
8-K 2019-07-25
8-K 2019-06-04
8-K 2019-04-25
8-K 2019-04-01
8-K 2019-03-20
8-K 2019-03-01
8-K 2019-02-21
8-K 2019-02-19
8-K 2019-02-19
8-K 2019-02-11
8-K 2019-02-07
8-K 2018-11-30
8-K 2018-10-04
8-K 2018-09-20
8-K 2018-09-05
8-K 2018-09-05
8-K 2018-08-22
8-K 2018-07-30
8-K 2018-06-26
8-K 2018-06-26
8-K 2018-06-06
8-K 2018-06-05
8-K 2018-04-26
8-K 2018-03-07
8-K 2018-02-08

FTV 10K Annual Report

Part I
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
Part II
Item 5. Market for The Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 6. [Reserved]
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Note 1. Business Overview and Basis for Presentation
Note 2. Summary of Significant Accounting Policies
Note 3. Acquisitions
Note 5. Inventories
Note 6. Property, Plant and Equipment
Note 7. Goodwill and Other Intangible Assets
Note 8. Fair Value Measurements
Note 9. Accrued Expenses and Other Liabilities
Note 10. Leases
Note 11. Financing
Note 12. Pension Plans
Note 13. Sales
Note 14. Income Taxes
Note 15. Restructuring and Other Related Charges
Note 16. Litigation and Contingencies
Note 17. Stock Based Compensation
Note 18. Capital Stock and Earnings per Share
Note 19. Segment Information
Note 20. Related - Party Transactions with Danaher
Note 21. Quarterly Data - Unaudited
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B. Other Information
Part III
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accountant Fees and Services
Part IV
Item 15. Exhibits and Financial Statement Schedules
Item 16. Form 10 - K Summary
EX-10.15 a20201231-ex1015.htm
EX-10.28 a20201231-ex1028.htm
EX-10.34 a20201231-ex1034.htm
EX-21.1 a20201231-ex211.htm
EX-23.1 a20201231-ex231.htm
EX-31.1 a20201231-ex311.htm
EX-31.2 a20201231-ex312.htm
EX-32.1 a20201231-ex321.htm
EX-32.2 a20201231-ex322.htm

Fortive Earnings 2020-12-31

Balance SheetIncome StatementCash Flow
2016128402015201620182020
Assets, Equity
2.21.81.30.90.40.02015201620182020
Rev, G Profit, Net Income
2.51.30.2-1.0-2.1-3.32015201620182020
Ops, Inv, Fin

ftv-20201231
false2020FY00016591660.40.40.01095700016591662020-01-012020-12-310001659166us-gaap:CommonStockMember2020-01-012020-12-310001659166us-gaap:ConvertiblePreferredStockMember2020-01-012020-12-31xbrli:shares00016591662021-02-19iso4217:USD00016591662020-06-2600016591662020-12-3100016591662019-12-31iso4217:USDxbrli:sharesxbrli:pure00016591662019-01-012019-12-310001659166us-gaap:ProductMember2020-01-012020-12-310001659166us-gaap:ProductMember2019-01-012019-12-310001659166us-gaap:ProductMember2018-01-012018-12-310001659166us-gaap:ServiceMember2020-01-012020-12-310001659166us-gaap:ServiceMember2019-01-012019-12-310001659166us-gaap:ServiceMember2018-01-012018-12-3100016591662018-01-012018-12-310001659166us-gaap:RetainedEarningsMember2020-01-012020-12-310001659166us-gaap:RetainedEarningsMember2019-01-012019-12-310001659166us-gaap:RetainedEarningsMember2018-01-012018-12-310001659166us-gaap:CommonStockMember2017-12-310001659166us-gaap:PreferredStockMember2017-12-310001659166us-gaap:AdditionalPaidInCapitalMember2017-12-310001659166us-gaap:RetainedEarningsMember2017-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001659166us-gaap:NoncontrollingInterestMember2017-12-310001659166us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001659166us-gaap:CommonStockMember2018-01-012018-12-310001659166us-gaap:PreferredStockMember2018-01-012018-12-310001659166us-gaap:NoncontrollingInterestMember2018-01-012018-12-310001659166us-gaap:CommonStockMember2018-12-310001659166us-gaap:PreferredStockMember2018-12-310001659166us-gaap:AdditionalPaidInCapitalMember2018-12-310001659166us-gaap:RetainedEarningsMember2018-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001659166us-gaap:NoncontrollingInterestMember2018-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001659166us-gaap:CommonStockMember2019-01-012019-12-310001659166us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001659166us-gaap:NoncontrollingInterestMember2019-01-012019-12-310001659166us-gaap:CommonStockMember2019-12-310001659166us-gaap:PreferredStockMember2019-12-310001659166us-gaap:AdditionalPaidInCapitalMember2019-12-310001659166us-gaap:RetainedEarningsMember2019-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001659166us-gaap:NoncontrollingInterestMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310001659166us-gaap:CommonStockMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001659166us-gaap:PreferredStockMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001659166us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001659166us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:NoncontrollingInterestMember2019-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001659166us-gaap:CommonStockMember2020-01-012020-12-310001659166us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001659166us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001659166us-gaap:CommonStockMember2020-12-310001659166us-gaap:PreferredStockMember2020-12-310001659166us-gaap:AdditionalPaidInCapitalMember2020-12-310001659166us-gaap:RetainedEarningsMember2020-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001659166us-gaap:NoncontrollingInterestMember2020-12-3100016591662018-12-3100016591662017-12-31ftv:country0001659166ftv:VontierMember2020-10-090001659166ftv:VontierMember2020-10-092020-10-090001659166ftv:VontierMemberus-gaap:SubsequentEventMember2021-01-192021-01-190001659166ftv:VontierMemberus-gaap:SubsequentEventMember2021-01-190001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Memberus-gaap:SubsequentEventMember2021-01-190001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-01-012020-12-310001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Memberus-gaap:SubsequentEventMember2021-01-190001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Member2019-03-010001659166ftv:ASBusinessMember2018-10-012018-10-010001659166ftv:ASBusinessMemberftv:AltraIndustrialMotionCorp.Member2018-10-012018-10-010001659166ftv:VontierMember2020-10-092020-10-090001659166srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-01-010001659166us-gaap:BuildingMember2020-01-012020-12-310001659166us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2020-01-012020-12-310001659166srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2020-01-012020-12-31iso4217:JPY0001659166ftv:YenTermLoanMember2020-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001659166ftv:AcquisitionsASPMember2019-04-012019-04-010001659166ftv:AcquisitionsASPMember2018-01-012018-12-310001659166ftv:AcquisitionsASPMember2020-01-012020-12-310001659166ftv:AcquisitionsASPMember2020-12-310001659166ftv:AcquisitionsASPMember2019-01-012019-12-31ftv:business0001659166us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-01-012019-12-310001659166us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-12-310001659166us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2018-01-012018-12-310001659166ftv:AcquisitionsAccruentMember2018-09-062018-09-06ftv:customer0001659166ftv:AcquisitionsAccruentMember2018-09-060001659166ftv:AcquisitionsAccruentMember2017-01-012017-12-310001659166ftv:AcquisitionsGordianMember2018-07-272018-07-270001659166ftv:AcquisitionsGordianMember2017-01-012017-12-310001659166ftv:AcquisitionsGordianMember2018-07-270001659166ftv:AcquisitionsAccruentandGordianMember2018-01-012018-12-310001659166ftv:Acquisitions2018Member2018-01-012018-12-310001659166ftv:Acquisitions2020Member2020-12-310001659166ftv:Acquisitions2019Member2019-12-310001659166ftv:Acquisitions2018Member2018-12-310001659166ftv:Acquisitions2020Member2020-01-012020-12-310001659166ftv:Acquisitions2019Member2019-01-012019-12-310001659166us-gaap:LineOfCreditMemberftv:DelayedDrawThreeYearTermLoanMemberftv:VontierMember2020-09-292020-09-290001659166us-gaap:LineOfCreditMemberftv:DelayedDrawThreeYearTermLoanMemberftv:VontierMember2020-09-290001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTwoYearTermLoanMemberftv:VontierMember2020-09-292020-09-290001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTwoYearTermLoanMemberftv:VontierMember2020-09-290001659166ftv:MultiCurrencyRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberftv:VontierMember2020-09-292020-09-290001659166ftv:MultiCurrencyRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberftv:VontierMember2020-09-290001659166ftv:VontierMember2020-09-292020-09-290001659166ftv:VontierMember2020-01-012020-12-310001659166ftv:VontierMember2019-01-012019-12-310001659166ftv:TelematicsReportingUnitMember2019-12-310001659166ftv:TelematicsReportingUnitMember2020-01-012020-03-270001659166ftv:TelematicsReportingUnitMember2020-03-27ftv:company0001659166ftv:ASBusinessMemberus-gaap:SegmentDiscontinuedOperationsMember2018-03-072018-03-070001659166ftv:ASBusinessMemberus-gaap:SegmentDiscontinuedOperationsMember2018-10-010001659166ftv:ASBusinessMemberus-gaap:SegmentDiscontinuedOperationsMember2018-10-012018-10-010001659166ftv:StevensHoldingCompanyInc.Memberftv:ASBusinessMemberus-gaap:SegmentDiscontinuedOperationsMember2018-10-012018-10-010001659166ftv:ASBusinessMemberus-gaap:SegmentDiscontinuedOperationsMember2018-01-012018-12-310001659166ftv:TelestreamLLCMember2019-07-202019-07-200001659166ftv:TelestreamLLCMember2019-07-200001659166ftv:TelestreamLLCMember2020-12-310001659166ftv:TelestreamLLCMember2019-12-310001659166ftv:TelestreamLLCMember2019-01-012019-12-310001659166ftv:TelestreamLLCMember2020-01-012020-12-310001659166us-gaap:LandAndLandImprovementsMember2020-12-310001659166us-gaap:LandAndLandImprovementsMember2019-12-310001659166ftv:BuildingandLeaseholdImprovementsMember2020-12-310001659166ftv:BuildingandLeaseholdImprovementsMember2019-12-310001659166us-gaap:MachineryAndEquipmentMember2020-12-310001659166us-gaap:MachineryAndEquipmentMember2019-12-31ftv:reporting_unit0001659166srt:MinimumMember2020-12-310001659166srt:MaximumMember2020-12-310001659166ftv:AdvancedHealthcareSolutionsMember2018-12-310001659166ftv:IntelligentOperatingSolutionsMember2018-12-310001659166ftv:PrecisionTechnologiesMember2018-12-310001659166ftv:AdvancedHealthcareSolutionsMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMember2019-12-310001659166ftv:IntelligentOperatingSolutionsMember2019-12-310001659166ftv:PrecisionTechnologiesMember2019-12-310001659166ftv:AdvancedHealthcareSolutionsMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMember2020-12-310001659166ftv:IntelligentOperatingSolutionsMember2020-12-310001659166ftv:PrecisionTechnologiesMember2020-12-310001659166ftv:PatentsAndTechnologyBasedIntangibleAssetsMember2020-12-310001659166ftv:PatentsAndTechnologyBasedIntangibleAssetsMember2019-12-310001659166ftv:CustomerRelationshipsAndOtherIntangiblesMember2020-12-310001659166ftv:CustomerRelationshipsAndOtherIntangiblesMember2019-12-310001659166us-gaap:TrademarksAndTradeNamesMember2020-12-310001659166us-gaap:TrademarksAndTradeNamesMember2019-12-310001659166us-gaap:TrademarksAndTradeNamesMember2020-12-310001659166us-gaap:TrademarksAndTradeNamesMember2019-12-310001659166ftv:CustomerRelationshipsandDevelopedTechnologyMember2020-01-012020-12-310001659166ftv:CustomerRelationshipsandDevelopedTechnologyMember2019-01-012019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001659166us-gaap:FairValueMeasurementsRecurringMember2020-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:FairValueMeasurementsRecurringMember2019-12-310001659166us-gaap:FairValueInputsLevel1Member2020-12-310001659166us-gaap:FairValueInputsLevel1Member2019-12-310001659166srt:MaximumMember2020-01-012020-12-310001659166ftv:USDollarDenominatedCommercialPaperMemberus-gaap:CommercialPaperMember2020-12-310001659166ftv:USDollarDenominatedCommercialPaperMemberus-gaap:CommercialPaperMember2019-12-310001659166ftv:EuroDenominatedCommercialPaperMemberus-gaap:CommercialPaperMember2020-12-310001659166ftv:EuroDenominatedCommercialPaperMemberus-gaap:CommercialPaperMember2019-12-310001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Member2020-12-310001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Member2019-12-310001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2020-12-310001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2019-12-310001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-12-310001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2019-12-310001659166us-gaap:LineOfCreditMemberftv:YenTermLoanMember2020-12-310001659166us-gaap:LineOfCreditMemberftv:YenTermLoanMember2019-12-310001659166ftv:SeniorUnsecuredNotesdue2021Memberus-gaap:SeniorNotesMember2020-12-310001659166ftv:SeniorUnsecuredNotesdue2021Memberus-gaap:SeniorNotesMember2019-12-310001659166ftv:SeniorUnsecuredNotesdue2026Memberus-gaap:SeniorNotesMember2020-12-310001659166ftv:SeniorUnsecuredNotesdue2026Memberus-gaap:SeniorNotesMember2019-12-310001659166ftv:SeniorUnsecuredNotesdue2046Memberus-gaap:SeniorNotesMember2020-12-310001659166ftv:SeniorUnsecuredNotesdue2046Memberus-gaap:SeniorNotesMember2019-12-310001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-12-310001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-12-310001659166ftv:OtherDebtMember2020-12-310001659166ftv:OtherDebtMember2019-12-310001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2020-04-240001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Member2020-04-240001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-04-240001659166us-gaap:RevolvingCreditFacilityMember2020-04-240001659166us-gaap:RevolvingCreditFacilityMember2020-12-310001659166us-gaap:LineOfCreditMember2020-04-232020-04-230001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMembersrt:ScenarioForecastMember2020-06-272021-04-020001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMembersrt:ScenarioForecastMember2021-07-022021-07-020001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMembersrt:ScenarioForecastMember2021-10-012021-10-010001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMembersrt:ScenarioForecastMember2021-12-312021-12-310001659166us-gaap:LineOfCreditMember2020-01-012020-12-310001659166us-gaap:LineOfCreditMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-232020-04-230001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMembersrt:ScenarioForecastMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-242021-12-310001659166us-gaap:LineOfCreditMemberus-gaap:BaseRateMember2020-04-232020-04-230001659166us-gaap:LineOfCreditMemberus-gaap:BaseRateMemberftv:TheAmendmentsMembersrt:ScenarioForecastMember2020-04-242021-12-310001659166us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2020-04-232020-04-230001659166srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-232020-04-230001659166us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2020-04-242021-12-310001659166srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-242021-12-310001659166us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2020-04-232020-04-230001659166srt:MaximumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2020-04-232020-04-230001659166us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembersrt:MinimumMember2020-04-242021-12-310001659166srt:MaximumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMember2020-04-242021-12-310001659166us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMembersrt:MinimumMember2020-04-232020-04-230001659166srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMember2020-04-232020-04-230001659166us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMember2020-04-242021-12-310001659166srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMemberus-gaap:LondonInterbankOfferedRateLIBORMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMember2020-04-242021-12-310001659166us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMember2020-04-232020-04-230001659166us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembersrt:MinimumMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMember2020-04-242021-12-310001659166srt:MaximumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMemberftv:DelayedDrawTermLoanDue2020ExtendedTrancheMember2020-04-242021-12-310001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMembersrt:ScenarioForecastMember2020-04-242021-12-310001659166us-gaap:LineOfCreditMemberftv:TheAmendmentsMember2020-04-240001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-02-222019-02-220001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-02-220001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesdue2022OverAllotmentOptionMember2019-02-220001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-01-012020-12-310001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-01-012019-12-310001659166us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-02-222019-02-220001659166us-gaap:ConvertibleDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberftv:SeniorConvertibleNotesDue2022Member2019-02-222019-02-220001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2019-10-250001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2019-10-252019-10-250001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2019-11-082019-11-080001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2019-11-080001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Memberus-gaap:LondonInterbankOfferedRateLIBORMember2019-11-082019-11-080001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2020-02-262020-02-260001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Member2020-10-092020-10-090001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Member2019-03-202019-03-200001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Memberus-gaap:LondonInterbankOfferedRateLIBORMember2019-03-012019-03-010001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2020Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-242020-04-240001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-03-230001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-03-232020-03-230001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-04-032020-04-030001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-04-032020-04-300001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-04-300001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-10-092020-10-090001659166us-gaap:LineOfCreditMemberftv:TermLoanDue2021Member2020-10-090001659166ftv:YenTermLoanMember2017-08-242017-08-240001659166ftv:YenTermLoanMember2017-08-240001659166ftv:YenTermLoanMember2017-08-282017-08-280001659166ftv:YenTermLoanMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-08-242017-08-240001659166ftv:YenTermLoanMember2020-10-150001659166ftv:YenTermLoanMember2020-10-152020-10-150001659166us-gaap:RevolvingCreditFacilityMember2016-06-162016-06-160001659166us-gaap:RevolvingCreditFacilityMember2016-06-160001659166us-gaap:RevolvingCreditFacilityMember2018-11-300001659166us-gaap:RevolvingCreditFacilityMember2018-11-302018-11-300001659166us-gaap:RevolvingCreditFacilityMember2019-12-310001659166us-gaap:RevolvingCreditFacilityMember2020-01-012020-12-310001659166ftv:InitialSeniorUnsecuredNotesdue2046Memberus-gaap:SeniorNotesMember2020-12-310001659166ftv:AdditionalSeniorUnsecuredNotesdue2046Memberus-gaap:SeniorNotesMember2020-12-310001659166ftv:SeniorUnsecuredNotesdue2021Memberus-gaap:SeniorNotesMember2020-11-130001659166ftv:SeniorUnsecuredNotesdue2021Memberus-gaap:SeniorNotesMember2020-11-132020-11-130001659166us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SeniorNotesMember2020-01-012020-12-310001659166ftv:TermLoanMember2020-12-310001659166us-gaap:SeniorNotesMember2020-12-310001659166ftv:VontierMemberus-gaap:SubsequentEventMember2021-01-190001659166us-gaap:SubsequentEventMember2021-01-190001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDue2020Memberus-gaap:SubsequentEventMember2021-01-192021-01-190001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Memberus-gaap:SubsequentEventMember2021-02-090001659166country:US2019-12-310001659166country:US2018-12-310001659166us-gaap:ForeignPlanMember2019-12-310001659166us-gaap:ForeignPlanMember2018-12-310001659166country:US2020-01-012020-12-310001659166country:US2019-01-012019-12-310001659166us-gaap:ForeignPlanMember2020-01-012020-12-310001659166us-gaap:ForeignPlanMember2019-01-012019-12-310001659166country:US2020-12-310001659166us-gaap:ForeignPlanMember2020-12-310001659166us-gaap:OtherAssetsMembercountry:US2020-12-310001659166us-gaap:OtherAssetsMembercountry:US2019-12-310001659166us-gaap:OtherAssetsMemberus-gaap:ForeignPlanMember2020-12-310001659166us-gaap:OtherAssetsMemberus-gaap:ForeignPlanMember2019-12-310001659166country:USftv:AccruedExpensesAndOtherCurrentLiabilitiesMember2020-12-310001659166country:USftv:AccruedExpensesAndOtherCurrentLiabilitiesMember2019-12-310001659166us-gaap:ForeignPlanMemberftv:AccruedExpensesAndOtherCurrentLiabilitiesMember2020-12-310001659166us-gaap:ForeignPlanMemberftv:AccruedExpensesAndOtherCurrentLiabilitiesMember2019-12-310001659166us-gaap:OtherNoncurrentLiabilitiesMembercountry:US2020-12-310001659166us-gaap:OtherNoncurrentLiabilitiesMembercountry:US2019-12-310001659166us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignPlanMember2020-12-310001659166us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignPlanMember2019-12-310001659166country:US2018-01-012018-12-310001659166us-gaap:ForeignPlanMember2018-01-012018-12-310001659166srt:MinimumMember2020-01-012020-12-310001659166srt:MinimumMember2019-01-012019-12-310001659166srt:MaximumMember2019-01-012019-12-310001659166srt:MinimumMember2018-01-012018-12-310001659166srt:MaximumMember2018-01-012018-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2020-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel3Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMember2020-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberftv:InsuranceContractMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberftv:InsuranceContractMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:InsuranceContractMemberus-gaap:FairValueInputsLevel3Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:InsuranceContractMember2020-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MutualFundMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberftv:OtherPrivateInvestmentMember2020-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesCommonStockMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesCommonStockMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesCommonStockMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesCommonStockMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberftv:DefinedBenefitPlanEquitySecuritiesPreferredStockMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:DefinedBenefitPlanEquitySecuritiesPreferredStockMemberus-gaap:FairValueInputsLevel2Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:DefinedBenefitPlanEquitySecuritiesPreferredStockMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:DefinedBenefitPlanEquitySecuritiesPreferredStockMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:MutualFundMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberftv:InsuranceContractMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberftv:InsuranceContractMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:InsuranceContractMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberftv:InsuranceContractMember2019-12-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:MutualFundMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberftv:OtherPrivateInvestmentMember2019-12-310001659166us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-12-310001659166us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-12-310001659166ftv:DeferredSalesCommissionsMembersrt:MinimumMember2020-12-310001659166srt:MinimumMember2019-12-310001659166srt:MaximumMember2019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-12-310001659166ftv:PeriodOneMember2021-01-012020-12-3100016591662021-01-01ftv:PeriodTwoMember2020-12-3100016591662021-01-01ftv:PeriodThreeMember2020-12-310001659166us-gaap:ProductMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:ProductMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:ProductMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166country:US2020-01-012020-12-310001659166country:USftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166country:USftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMembercountry:USus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166country:CN2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-12-310001659166ftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-12-310001659166ftv:MedicalMember2020-01-012020-12-310001659166ftv:MedicalMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:MedicalMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:MedicalMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:IndustrialManufacturingMember2020-01-012020-12-310001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:IndustrialManufacturingMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:UtilitiesPowerMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:GovernmentMember2020-01-012020-12-310001659166us-gaap:GovernmentMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:GovernmentMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMember2020-01-012020-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AerospaceAndDefenseMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AerospaceAndDefenseMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:OilAndGasMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:OilAndGasMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:RetailAndConsumerMember2020-01-012020-12-310001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:OtherDirectEndMarketsMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:DirectEndMarketsMember2020-01-012020-12-310001659166ftv:DirectEndMarketsMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:DirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:OtherDistributorsMember2020-01-012020-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:PrecisionTechnologiesMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001659166us-gaap:ProductMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:ProductMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:ProductMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166country:US2019-01-012019-12-310001659166country:USftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166country:USftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMembercountry:USus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166country:CN2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:CN2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:CN2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:CN2019-01-012019-12-310001659166ftv:CountriesExcludingUnitedStatesandChinaMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2019-01-012019-12-310001659166ftv:MedicalMember2019-01-012019-12-310001659166ftv:MedicalMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:MedicalMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:MedicalMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:IndustrialManufacturingMember2019-01-012019-12-310001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:IndustrialManufacturingMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:UtilitiesPowerMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:GovernmentMember2019-01-012019-12-310001659166us-gaap:GovernmentMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:GovernmentMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMember2019-01-012019-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AerospaceAndDefenseMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AerospaceAndDefenseMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:OilAndGasMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:OilAndGasMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:RetailAndConsumerMember2019-01-012019-12-310001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:OtherDirectEndMarketsMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:DirectEndMarketsMember2019-01-012019-12-310001659166ftv:DirectEndMarketsMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:DirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:OtherDistributorsMember2019-01-012019-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:PrecisionTechnologiesMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001659166us-gaap:ProductMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:ProductMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:ProductMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166country:US2018-01-012018-12-310001659166country:USftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166country:USftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMembercountry:USus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166country:CN2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:CN2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:CN2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:CN2018-01-012018-12-310001659166ftv:CountriesExcludingUnitedStatesandChinaMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2018-01-012018-12-310001659166ftv:MedicalMember2018-01-012018-12-310001659166ftv:MedicalMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:MedicalMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:MedicalMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:IndustrialManufacturingMember2018-01-012018-12-310001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:IndustrialManufacturingMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:UtilitiesPowerMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:UtilitiesPowerMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:GovernmentMember2018-01-012018-12-310001659166us-gaap:GovernmentMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:GovernmentMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMember2018-01-012018-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AerospaceAndDefenseMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AerospaceAndDefenseMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:OilAndGasMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:OilAndGasMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:RetailAndConsumerMember2018-01-012018-12-310001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:OtherDirectEndMarketsMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:DirectEndMarketsMember2018-01-012018-12-310001659166ftv:DirectEndMarketsMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:DirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:OtherDistributorsMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:PrecisionTechnologiesMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001659166us-gaap:DomesticCountryMember2020-12-310001659166us-gaap:DomesticCountryMember2019-12-310001659166us-gaap:ForeignCountryMember2020-12-310001659166us-gaap:ForeignCountryMember2019-12-310001659166us-gaap:StateAndLocalJurisdictionMember2020-12-310001659166us-gaap:EmployeeSeveranceMember2020-01-012020-12-310001659166us-gaap:EmployeeSeveranceMember2019-01-012019-12-310001659166us-gaap:EmployeeSeveranceMember2018-01-012018-12-310001659166us-gaap:FacilityClosingMember2020-01-012020-12-310001659166us-gaap:FacilityClosingMember2019-01-012019-12-310001659166us-gaap:FacilityClosingMember2018-01-012018-12-310001659166us-gaap:EmployeeSeveranceMember2018-12-310001659166us-gaap:EmployeeSeveranceMember2019-12-310001659166us-gaap:EmployeeSeveranceMember2020-12-310001659166us-gaap:OtherRestructuringMember2018-12-310001659166us-gaap:OtherRestructuringMember2019-01-012019-12-310001659166us-gaap:OtherRestructuringMember2019-12-310001659166us-gaap:OtherRestructuringMember2020-01-012020-12-310001659166us-gaap:OtherRestructuringMember2020-12-310001659166us-gaap:CostOfSalesMember2020-01-012020-12-310001659166us-gaap:CostOfSalesMember2019-01-012019-12-310001659166us-gaap:CostOfSalesMember2018-01-012018-12-310001659166us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001659166us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001659166us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-3100016591662016-07-020001659166us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001659166us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001659166us-gaap:RestrictedStockMember2020-01-012020-12-310001659166ftv:PerformanceStockUnitsMember2020-01-012020-12-310001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2020-01-012020-12-310001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2019-01-012019-12-310001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2018-01-012018-12-310001659166us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001659166us-gaap:EmployeeStockOptionMember2018-01-012018-12-310001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2020-12-310001659166us-gaap:EmployeeStockOptionMember2020-12-310001659166us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-01-012020-12-310001659166us-gaap:EmployeeStockOptionMembersrt:MaximumMember2020-01-012020-12-310001659166us-gaap:EmployeeStockOptionMembersrt:MinimumMember2019-01-012019-12-310001659166us-gaap:EmployeeStockOptionMembersrt:MaximumMember2019-01-012019-12-310001659166us-gaap:EmployeeStockOptionMembersrt:MinimumMember2018-01-012018-12-310001659166us-gaap:EmployeeStockOptionMembersrt:MaximumMember2018-01-012018-12-310001659166ftv:ExercisePriceRange1067To2122Membersrt:MinimumMember2020-01-012020-12-310001659166srt:MaximumMemberftv:ExercisePriceRange1067To2122Member2020-01-012020-12-310001659166ftv:ExercisePriceRange1067To2122Member2020-12-310001659166ftv:ExercisePriceRange1067To2122Member2020-01-012020-12-310001659166ftv:ExercisePriceRange2123To3531Membersrt:MinimumMember2020-01-012020-12-310001659166ftv:ExercisePriceRange2123To3531Membersrt:MaximumMember2020-01-012020-12-310001659166ftv:ExercisePriceRange2123To3531Member2020-12-310001659166ftv:ExercisePriceRange2123To3531Member2020-01-012020-12-310001659166ftv:ExercisePriceRange3532To5169Membersrt:MinimumMember2020-01-012020-12-310001659166srt:MaximumMemberftv:ExercisePriceRange3532To5169Member2020-01-012020-12-310001659166ftv:ExercisePriceRange3532To5169Member2020-12-310001659166ftv:ExercisePriceRange3532To5169Member2020-01-012020-12-310001659166ftv:ExercisePriceRange5170To6385Membersrt:MinimumMember2020-01-012020-12-310001659166srt:MaximumMemberftv:ExercisePriceRange5170To6385Member2020-01-012020-12-310001659166ftv:ExercisePriceRange5170To6385Member2020-12-310001659166ftv:ExercisePriceRange5170To6385Member2020-01-012020-12-310001659166ftv:ExercisePriceRange6386To7153Membersrt:MinimumMember2020-01-012020-12-310001659166srt:MaximumMemberftv:ExercisePriceRange6386To7153Member2020-01-012020-12-310001659166ftv:ExercisePriceRange6386To7153Member2020-12-310001659166ftv:ExercisePriceRange6386To7153Member2020-01-012020-12-310001659166us-gaap:StockCompensationPlanMember2017-12-310001659166us-gaap:StockCompensationPlanMember2018-01-012018-12-310001659166us-gaap:StockCompensationPlanMember2018-12-310001659166us-gaap:StockCompensationPlanMember2019-01-012019-12-310001659166us-gaap:StockCompensationPlanMember2019-12-310001659166us-gaap:StockCompensationPlanMember2020-01-012020-12-310001659166us-gaap:StockCompensationPlanMember2020-12-31ftv:vote00016591662020-01-012020-03-2700016591662020-03-282020-06-2600016591662020-06-272020-09-2500016591662020-09-262020-12-3100016591662019-01-012019-03-2900016591662019-03-302019-06-2800016591662019-06-292019-09-2700016591662019-09-282019-12-310001659166us-gaap:SubsequentEventMember2021-01-262021-01-2600016591662018-06-2900016591662018-01-012018-06-290001659166us-gaap:OverAllotmentOptionMember2018-06-290001659166us-gaap:ConvertiblePreferredStockMember2018-01-012018-06-290001659166srt:ScenarioForecastMemberus-gaap:ConvertiblePreferredStockMembersrt:MinimumMember2021-07-010001659166srt:MaximumMembersrt:ScenarioForecastMemberus-gaap:ConvertiblePreferredStockMember2021-07-01ftv:day0001659166us-gaap:ConvertiblePreferredStockMemberus-gaap:SubsequentEventMember2021-01-262021-01-260001659166us-gaap:ConvertiblePreferredStockMember2019-01-012019-12-310001659166us-gaap:ConvertiblePreferredStockMember2018-01-012018-12-31ftv:segment0001659166us-gaap:CorporateNonSegmentMember2020-01-012020-12-310001659166us-gaap:CorporateNonSegmentMember2019-01-012019-12-310001659166us-gaap:CorporateNonSegmentMember2018-01-012018-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2019-12-310001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2018-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2019-12-310001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2018-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-12-310001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2018-12-310001659166us-gaap:OperatingSegmentsMember2020-12-310001659166us-gaap:OperatingSegmentsMember2019-12-310001659166us-gaap:OperatingSegmentsMember2018-12-310001659166us-gaap:CorporateNonSegmentMember2020-12-310001659166us-gaap:CorporateNonSegmentMember2019-12-310001659166us-gaap:CorporateNonSegmentMember2018-12-310001659166us-gaap:SegmentDiscontinuedOperationsMember2020-12-310001659166us-gaap:SegmentDiscontinuedOperationsMember2019-12-310001659166us-gaap:SegmentDiscontinuedOperationsMember2018-12-310001659166country:US2020-12-310001659166country:US2019-12-310001659166country:US2018-12-310001659166country:CH2020-12-310001659166country:CH2019-12-310001659166country:CH2018-12-310001659166ftv:CountriesExcludingUnitedStatesAndSwitzerlandMember2020-12-310001659166ftv:CountriesExcludingUnitedStatesAndSwitzerlandMember2019-12-310001659166ftv:CountriesExcludingUnitedStatesAndSwitzerlandMember2018-12-310001659166us-gaap:AllowanceForCreditLossMember2019-12-310001659166us-gaap:AllowanceForCreditLossMember2020-01-012020-12-310001659166us-gaap:AllowanceForCreditLossMember2020-12-310001659166us-gaap:AllowanceForCreditLossMember2018-12-310001659166us-gaap:AllowanceForCreditLossMember2019-01-012019-12-310001659166us-gaap:AllowanceForCreditLossMember2017-12-310001659166us-gaap:AllowanceForCreditLossMember2018-01-012018-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to            
Commission File Number 1-37654
____________
FORTIVE CORPORATION
(Exact name of registrant as specified in its charter)

Delaware 47-5654583
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. employer
identification number)

6920 Seaway Blvd
Everett,WA98203
(Address of principal executive offices)(Zip code)

Registrant’s telephone number, including area code: (425) 446 - 5000

Securities Registered Pursuant to Section 12(b) of the Act:
 
Title of each classTrading symbolsName of each exchange on which registered
Common stock, par value $0.01 per shareFTVNew York Stock Exchange
5% Mandatory convertible preferred stock, Series A, par value $0.01 per shareFTV. PRANew York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:
NONE
(Title of Class)
Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.
Yes x No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x



Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerx  Accelerated filer    ¨
Non-accelerated filer     ¨(Do not check if a smaller reporting company)Smaller reporting company     
Emerging growth company     
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No ý
As of February 19, 2021 there were 338,072,765 shares of Registrant’s common stock outstanding. The aggregate market value of common stock held by non-affiliates of the Registrant as of June 26, 2020 was $17.1 billion, based upon the closing price of the Registrant’s common stock on the New York Stock Exchange.
 ____________________________________
DOCUMENTS INCORPORATED BY REFERENCE
Part III incorporates certain information by reference from the Registrant’s proxy statement for its 2021 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after Registrant’s fiscal year-end. With the exception of the sections of the 2021 Proxy Statement specifically incorporated herein by reference, the 2021 Proxy Statement is not deemed to be filed as part of this Form 10-K.


Table of Contents
TABLE OF CONTENTS
 
Page
Part 1.
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Part 2.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Part 3.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Part 4.
Item 15.
Item 16.

1

Table of Contents
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this Annual Report, in other documents we file with or furnish to the Securities and Exchange Commission (“SEC”), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are “forward-looking statements” within the meaning of the United States federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other financial measures; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions, divestitures, separation into two independent, publicly traded companies, strategic opportunities, securities offerings, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets we sell into, including the expected impact of trade and tariff policies; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; impact of changes to tax laws; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risks and uncertainties set forth under “Item 1A. Risk Factors” in this Annual Report.
Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments, and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they are made (or such earlier date as may be specified in such statement). We do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
PART I
ITEM 1. BUSINESS
General
Fortive Corporation is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our well-known brands hold leading positions in intelligent operating solutions, precision technologies, and advanced healthcare solutions. Our businesses design, develop, service, manufacture, and market professional and engineered products, software, and services for a variety of end markets, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries across North America, Asia Pacific, Europe, and Latin America.
We are guided by our shared purpose to deliver essential technology for the people who accelerate progress, and we are united by our culture of continuous improvement and bias for action that embody the Fortive Business System (“FBS”). Through rigorous application of the proprietary set of growth, lean, and leadership tools and processes that comprise FBS, we continuously improve business performance in the critical areas of innovation, product development and commercialization, global supply chain, sales and marketing, and leadership development. Our commitment to FBS has enabled us to drive customer satisfaction and profitability, and generate significant improvements in innovation, growth, and core operating margins. Additionally, FBS has enabled us to execute a disciplined acquisition strategy and expand our portfolio into new and attractive markets furthering our goal of creating long-term shareholder value.
On October 9, 2020, we completed the separation of our former Industrial Technologies segment (the “Separation”) by distributing 80.1% of the outstanding shares of Vontier Corporation (“Vontier”), the entity we created to hold the corresponding businesses, to Fortive stockholders on a pro rata basis. To effect the Separation, the Company distributed to its stockholders two shares of Vontier common stock for every five shares of the Company’s common stock outstanding held on September 25, 2020, the record date for the distribution, with the Company retaining 19.9% of the shares of Vontier common stock immediately following the Separation (the “Retained Vontier Shares”). On January 19, 2021, we completed an exchange of all
2

Table of Contents
of the Retained Vontier Shares as part of a non-cash debt-for-equity exchange that reduced outstanding indebtedness of Fortive by $1.1 billion.
On October 1, 2018, we completed the split-off of businesses in our automation and specialty platform (excluding our Hengstler and Dynapar businesses) (the “A&S Business”) to our shareholders who elected to exchange shares of our common stock for all issued and outstanding shares of Stevens Holding Company, Inc. (“Stevens”), the entity we incorporated to hold the A&S Business. The split-off was immediately followed by the merger of Stevens with a subsidiary of Altra Industrial Motion Corp. (“Altra”). Concurrently with the split-off, we sold directly to Altra the remainder of the assets and liabilities of the A&S Business that were not otherwise contributed to Stevens.
Fortive Corporation is a Delaware corporation and was incorporated in 2015 in connection with the separation of Fortive from Danaher Corporation (“Danaher” or “Former Parent”) on July 2, 2016 as an independent, publicly-traded company, listed on the New York Stock Exchange.
In this Annual Report, the terms “Fortive” or the “Company” refer to either Fortive Corporation or to Fortive Corporation and its consolidated subsidiaries, as the context requires. Unless otherwise indicated, all amounts in this Annual Report refer to continuing operations.
Reportable Segments
Before the Separation, we reported our results in two reportable segments consisting of Professional Instrumentation and Industrial Technologies. In connection with the Separation, and in light of organizational and leadership changes we made to enhance and better evaluate the operational performance of and allocate resources to our businesses, we now operate and report our results in three segments, Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions, each of which is further described below.
Intelligent Operating Solutions
Our Intelligent Operating Solutions segment provides leading solutions to accelerate industrial and facility reliability and performance, as well as compliance and safety across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others. The businesses in our Intelligent Operating Solutions segment provide a broad and differentiated offering of instrumentation, sensors, software, and services to address these critical workflows for our customers. These offerings include connected reliability tools, environment, health, safety, and quality (EHSQ) enterprise software products, facility and asset lifecycle software, and pre-construction planning and construction procurement solutions. We also offer a series of leading hardware offerings including ruggedized professional test tools, electric, pressure, and temperature calibration tools for high-end government and industrial labs, as well as portable gas detection tools which keep workers safe in industries where air quality and safety cannot be taken for granted. Typical users of these offerings include electrical engineers, electricians, electronic technicians, EHSQ professionals, network technicians, facility managers, first-responders, and maintenance professionals.
Products and services within our Intelligent Operating Solutions segment are marketed under a variety of leading brands, including ACCRUENT, FLUKE, FLUKE NETWORKS, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, and PRUFTECHNIK.
Precision Technologies
Our Precision Technologies segment supplies technologies to a broad set of vertical end markets, enabling our customers to accelerate the development of innovative products and solutions. We provide our customers with electrical test and measurement instruments and services, energetic material devices, and a broad portfolio of sensor and control system solutions. In our sensing business, we provide solutions that sense, monitor, and control operational or manufacturing variables, such as temperature, pressure, level, and flow. Our sensing products serve a wide variety of vertical markets, including power and energy, medical equipment, food and beverage, aerospace and defense, off-highway vehicles, electronics, semiconductors, and other general industrial markets. In our energetic materials business, we design, manufacture, and market highly-engineered energetic material solutions for commercial, defense, and space markets. At Tektronix, we provide our customers with a broad portfolio of test and measurement instruments serving a variety of end markets including communication, consumer electronics, semiconductor, defense, automotive, and industrial. Customers for these products and services include design engineers for advanced electronic devices and equipment, process and quality engineers focused on improved process capability and
3

Table of Contents
productivity, facility maintenance managers driving increased uptime, and other customers for whom precise measurement, reliability, and compliance are critical in their applications.
Products and services in our Precision Technologies segment are marketed under a variety of brands, including ANDERSON-NEGELE, GEMS, SETRA, HENGSTLER-DYNAPAR, QUALITROL, PACIFIC SCIENTIFIC, KEITHLEY and TEKTRONIX.
Advanced Healthcare Solutions
Our Advanced Healthcare Solutions segment serves healthcare customers with enabling products and services for critical activities that help ensure safe, efficient, and timely healthcare. Through the Advanced Healthcare Solutions segment, we provide broad hardware and software portfolio offerings optimized around our end-users’ most critical workflows, including instrument and device reprocessing, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation safety monitoring, and asset management. Our offerings provide critical sterilization and disinfection solutions, including low-temperature hydrogen peroxide sterilization solutions and advanced infection prevention and patient safety in healthcare facilities. In addition, we provide subscription-based surgical inventory management systems to healthcare facilities to facilitate inventory management and regulatory compliance as well as subscription-based technical, analytical, and compliance services to determine radiation exposure. Furthermore, through our solutions and services, we enable developers and engineers in healthcare and other critical industries across the end-to-end product creation cycle from concepts to finished products.
Products and services in our Advanced Healthcare Solutions segment are marketed under a variety of brands, including ASP, CENSIS, CENSITRAC, EVOTECH, FLUKE BIOMEDICAL, INVETECH, LANDAUER, RAYSAFE, and STERRAD.
************************************
The following discussion includes information common to all of our segments.
Materials
Our manufacturing operations employ a wide variety of raw materials, including electronic components, steel, plastics and other petroleum-based products, cast iron, aluminum, and copper. Prices of oil and gas affect our costs for freight and utilities. We purchase raw materials from a large number of independent sources around the world. Tariffs affect our costs for impacted materials or components we import into the United States. No single supplier is material, although for some components that require particular specifications or qualifications there may be a single supplier or a limited number of suppliers that can readily provide such components. We utilize a number of techniques to address potential disruption in and other risks relating to our supply chain, including in certain cases the use of safety stock, alternative materials, and qualification of multiple supply sources. During 2020 we had no raw material shortages that had a material effect on our business. For a further discussion of risks related to the materials and components required for our operations, please refer to “Item 1A. Risk Factors.”
Intellectual Property
We own numerous patents, trademarks, copyrights, and trade secrets and hold licenses to use intellectual property owned by others. Although in aggregate our intellectual property is important to our operations, we do not consider any single patent, trademark, copyright, trade secret, or license to be of material importance to any segment or to the business as a whole. From time to time we engage in litigation to protect our intellectual property rights. For a discussion of risks related to our intellectual property, please refer to “Item 1A. Risk Factors.” All capitalized brands and product names throughout this document are trademarks owned by, or licensed to, Fortive.
Competition
We believe that we are a leader in many of our served markets. Although our businesses generally operate in highly competitive markets, our competitive position cannot be determined accurately in the aggregate or by segment, since none of our competitors offer all of the same product and service lines or serve all of the same markets as we do. Because of the range of the products and services we sell and the variety of markets we serve, we encounter a wide variety of competitors, including larger companies or divisions of larger companies with substantial sales, marketing, research, and financial capabilities, as well as well-established regional competitors who are more specialized than we are in particular markets. We face increased competition in a number of our served markets as a result of the entry of competitors based in low-cost manufacturing locations, and increasing consolidation in particular markets. The number of competitors varies by product and service line. Our management believes that we have a market leadership position in most of the markets we serve. Key competitive factors vary among our businesses and product and service lines, but include the specific factors noted above with respect to each particular business and typically also include price, quality, performance, delivery speed, applications expertise, distribution channel
4

Table of Contents
access, service and support, technology and innovation, breadth of product, service and software offerings, and brand name recognition. For a discussion of risks related to competition, please refer to “Item 1A. Risk Factors.”
Seasonal Nature of Business
General economic conditions impact our business and financial results, and certain of our businesses experience seasonal and other trends related to the industries and end markets that they serve. For example, capital equipment sales are often stronger in the fourth calendar quarter and sales to OEMs are often stronger immediately preceding and following the launch of new products. However, as a whole, we are not subject to material seasonality.
Human Capital Resources
Empowering our talented global team to contribute in meaningful ways is a critical component of our strategy and our success. To support the advancement of our employees and the success of our Company, we invest in and develop our employees at every level. We are committed to creating a challenging and collaborative culture and environment where our employees can grow, develop, and do their best work.
COVID-19 Response
In the uncertainty that immediately followed the COVID-19 pandemic, we were guided by five key pillars in our response to our employees: Safety, Transparency, Empathy, Science and Employee Trust. The policies we implemented were guided with the safety of our employees, their families, our customers, and our communities as the number one priority, with our actions informed by data and expert public health guidance. The manner in which we considered and communicated our policies and actions were driven by the recognition of, and empathy for, the uncertainty, fear, and real-life impact caused by the pandemic for our colleagues. With that in mind, we focused on being agile and transparent with what we were doing and why we were doing it, while listening to ongoing feedback from our global teams and quickly making changes where needed. We did our best to accommodate the needs of our people as they managed through an incredibly difficult year personally and professionally.
Driven by our values, we:
Formed global and local response teams at every level to create hundreds of standard processes to share best practices and streamline communication to keep our employees safe and informed;
Acted quickly to limit and then stop business travel;
Ensured pay continuity for quarantine periods for our employees;
Quickly made the decision to enable and then mandate remote work for those who were able to do so while ensuring that our essential manufacturing team members had the education, resources, and support needed to stay safe on the job;
Created flexible shifts and schedules to accommodate childcare and other family or personal needs;
Provided subsidized childcare and other caregiver services as well as parental counseling;
Waived deductibles, co-pays, and co-insurance for COVID-19 testing or treatment as well as all virtual healthcare visits; and
Provided enhanced counseling and mental health coverage and services.
Employee Profile and Development
As of December 31, 2020, we employed approximately 17,000 persons, of whom approximately 9,500 were employed in the United States and approximately 7,500 were employed outside of the United States. Outside the United States, we have government-mandated collective bargaining arrangements and union contracts in certain countries, particularly in Europe where certain of our employees are represented by unions and/or works councils.
Human Capital Strategy
Our Human Capital Strategy is designed to attract, retain, and develop the best talent to drive our business strategy forward by offering a competitive reward structure and a compelling employee value proposition. A key element of our value proposition is our commitment to our employees’ continued learning, development, and success. To respond to our growing business and technology changes, our Leadership, Development & Learning team has adopted a blended learning approach that combines online digital learning with classroom teaching and coaching to effectively scale continuous learning and accelerate our ability to learn quickly and remain agile throughout Fortive. With the challenges presented by the COVID-19 pandemic, we further enhanced our virtual and online learning and development platform to ensure safety of our employees without compromising our commitment to our employees’ ongoing career success.
5

Table of Contents
The following is a summary of some of the key support we provide to our employees to further their learning and development:
The Fortive9
The Fortive9 is our leadership framework that is critical to how we guide the development of our employees because Fortive9 is how we aspire to work, deliver value, and build organization capability. Examples of the Fortive 9 include Customer Obsessed, Innovation, and Team and Talent Development.
People Leader Experience
Comprehensive learning for both new and experienced leaders, harnessing the best of interactive learning, and providing the critical tools as our employees assume greater people leadership responsibilities throughout their career with us.
Accelerated Leadership Experience (ALE)
Designed for high performing employees as preparation for running Fortive businesses or functions. We use immersive, experiential learning, where individuals can drive personal progress and overcome obstacles to fulfill their leadership potential.
FBS Office and University
FBS Office is dedicated to strategically imbed FBS in everything we do, from innovations to operations. FBS University, our proprietary virtual and hands-on learning environment, develops and reinforces learning for hundreds of FBS Champions across our Company each year to deliver value.
FBS Ignite
An immersive development experience that leverages the diversity of our operating companies. Supported with intensive development in the FBS toolset, active mentoring from the FBS Office, and executive career coaching, participants advance their FBS expertise and business acumen.
Growth Accelerator
A key development experience that enables our team to solve challenges in new, inspiring ways through three key innovation tools, Deep Customer Insight, Solution Generation, and Experimentation, each designed to enable our employees to develop critical solutions for customers.
Each one of these investments in our team delivers value to both our people and our customers, with the investments focused on development that adds most value to stakeholders.
Inclusion and Diversity
We believe that creating inclusive places to work and diverse points of view are the lifeblood of innovation and growth and provide us with a strategic advantage. In 2020, we continued to make significant strides to reflect the needs, priorities, and experiences of our global team and strengthen our culture of inclusion and diversity. Our Board of Directors and our Compensation Committee oversee our human capital management strategies, including our inclusion and diversity efforts. Our VP, Inclusion & Diversity works closely with our senior management and our Inclusion & Diversity Council, involving employees at every level in establishing a collaborative vision that will truly reflect the needs, priorities, and viewpoints of our diverse global team.
6

Table of Contents
Our inclusion and diversity strategies are founded on the following pillars, using the insights from employees, community, and other stakeholders:
Strategic Pillar
ftv-20201231_g1.jpg
Inclusion and Diversity Matters:
Build a diverse Fortive through hiring, developing, and retaining a strong team
ftv-20201231_g2.jpg
Everyone Owns Inclusion:
Invest in development of our teams to build a Fortive where you can be yourself and do your best work

ftv-20201231_g3.jpg
I&D in Our DNA:
Build a culture of equity that enables greater innovation for customers and the world


Please refer to our Proxy Statement for more details about our progress against these pillars.
Engagement and Communication
A key focus of our human capital management strategy is active listening and effective communication throughout the organization. Our senior leaders are committed to actively listen to our employees and other stakeholders, as demonstrated by over one hundred separate “Courageous Conversations” held in 2020 to actively listen and learn on race and social justice matters so we can make a real impact with our actions. In addition, in 2020, we conducted several employee surveys focused on getting feedback on actions related to our COVID-19 response work. We wanted to ensure our teams had the best support possible through such an extremely challenging time. This allowed for us to listen, learn, and adjust quickly to the needs of our teams across the globe. Based on the learnings from 2020, we have adjusted our approach to employee experience surveys and feedback. Beginning in 2021, we have moved from an annual survey to shorter quarterly employee experience surveys and a more thorough biennial survey. This will enable us to be more responsive to the needs and feedback from the organization while enhancing our ability to understand trends over time. The results inform both management and the Board of Directors on appropriate actions and strategies to continuously enhance our employees’ experience.
Government Contracts
Although the substantial majority of our revenue in 2020 was from customers other than governmental entities, each of our segments has agreements relating to the sale of products to government entities. As a result, we are subject to various statutes and regulations that apply to companies doing business with governments and government-owned entities. For a discussion of risks related to government contracting requirements, please refer to “Item 1A. Risk Factors.”
Regulatory Matters
We face extensive government regulation both within and outside the United States relating to the development, manufacture, marketing, sale, and distribution of our products, software, and services. The following sections describe certain significant regulations that we are subject to. These are not the only regulations that our businesses must comply with. For a description of the risks related to the regulations that our businesses are subject to, please refer to “Item 1A. Risk Factors.”
Medical Device Regulations
Many of our products in the Advanced Healthcare Solutions segment are classified as medical devices and are subject to restrictions under domestic and foreign laws, rules, regulations, self-regulatory codes, circulars, and orders, including, but not limited to, the U.S. Food, Drug, and Cosmetic Act (the “FDCA”). The FDCA requires these products, when sold in the United States, to be safe and effective for their intended uses and to comply with the regulations administered by the U.S. Food and Drug Administration (“FDA”). The FDA regulates the design, development, research, preclinical and clinical testing, introduction, manufacture, advertising, labeling, packaging, marketing, distribution, import and export, and record keeping for such products.
7

Table of Contents
Medical devices can be marketed only for the indications for which they are cleared or approved. After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture, or intended use, may require a new 510(k) clearance and payment of an FDA user fee.
Market access, sales, and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example in the European Economic Area (“EEA”), a medical device must meet the Medical Devices Directive’s (“MDD”) Essential Requirements or, effective May 26, 2021, the Medical Devices Regulation’s (“MDR”) General Safety and Performance Requirements. Before placing a medical device on the EEA market, the manufacturer must prepare a declaration of conformity, certifying that the device complies with the MDD/MDR, and must then affix the CE mark. The notified body typically audits and examines the device’s technical documentation, and the quality system for the manufacture, design, and final inspection of the relevant device before issuing a CE certificate. Following the issuance of this CE certificate, manufacturers may prepare the declaration of conformity and affix the CE mark to the devices covered by this CE certificate. Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.
Any medical devices we manufacture and distribute are subject to pervasive and continuing regulation by the FDA and certain state and certain other comparable foreign authorities. As a medical device manufacturer, our manufacturing facilities are subject to inspection on a routine basis by the FDA and other comparable foreign authorities as well as audits by our notified body. We are required to adhere to the Current Good Manufacturing Practices requirements, as set forth in the Quality Systems Regulation, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all phases of the design and manufacturing process.
We must also comply with global post-market surveillance regulations, including adverse event reporting requirements, which require that we review and report to the FDA and other comparable foreign authorities any incident in which our products may have caused or contributed to a death or serious injury. We must also report any incident in which our product has malfunctioned if that malfunction would likely cause or contribute to a death or serious injury if it were to recur.
Labeling and promotional activities are subject to scrutiny by the FDA and other comparable foreign authorities and, in certain circumstances, by the Federal Trade Commission and other comparable foreign regulators. Medical devices approved or cleared by the FDA, foreign regulators, or our notified body may not be promoted for undocumented, unapproved, or uncleared uses, otherwise known as “off-label” promotion. The FDA, other U.S. agencies, and other comparable foreign authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.
Other Healthcare Laws
We are subject to various healthcare related laws regulating fraud and abuse, research and development, pricing and sales and marketing practices, and the privacy and security of health information. In particular, the U.S. Federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration (including any kickback or bribe), directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made in whole or in part under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Similar laws and regulations apply in many foreign countries.
The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) prohibits knowingly and willfully (1) executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors, or (2) falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, also restricts the use and disclosure of patient identifiable health information, mandates the adoption of standards relating to the privacy and security of patient identifiable health information, and requires the reporting of certain security breaches with respect to such information. Similar to the U.S. Federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation. Similar laws and regulations apply in many foreign countries.
The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program, knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly makes a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false
8

Table of Contents
claim to the federal government, and to share in any monetary recovery. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Similar laws and regulations apply in many foreign countries.
Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. Analogous U.S. state laws and regulations, such as state anti-kickback and false claims laws, also may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements, and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers. Further, there are state laws that require medical device manufacturers to comply with the voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA. Similar laws and regulations apply in many non-U.S. countries.
Anti-Bribery and Anti-Corruption Laws
Given the international scope of operation, we are subject to various U.S. and non-U.S. laws outlawing bribes, kickbacks, payoffs, and other improper payments. In particular, the U.S. Foreign Corrupt Practices Act (“FCPA”), the UK Bribery Act, and other similar laws in other jurisdictions prohibit companies, their officers and employees, and their intermediaries from making improper payments to public officials to influence those officials or secure an improper advantage in order to obtain or retain business. In the past several years, there has been a substantial increase in the enforcement of these global anti-bribery and anti-corruption laws. Our operations throughout the world, including in developing countries with heightened risks of corruption, and interactions with individuals who are considered public officials under these laws, such as healthcare professionals in countries with state-run healthcare systems, expose us to the risk of violating these laws. Violations of these laws or even allegations of violations of these laws could pose reputational risks, subject us to investigations and related litigation, cause disruptions to our business, and result in monetary fines and damages and other sanctions.
Data Privacy and Security Laws
As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal, and/or sensitive data in the course of our business. For example, in the United States, HIPAA privacy and security rules require certain of our operations to maintain controls to protect the availability and confidentiality of patient health information, individual states regulate data breach and security requirements, and multiple governmental bodies assert authority over aspects of the protection of personal privacy.
Data privacy and security laws are rapidly evolving. In particular, a new, broad privacy law in California, the California Consumer Privacy Act (“CCPA”), came into effect in January 2020. The CCPA has some of the same features as the GDPR (discussed below), and has already prompted several other states to consider similar legislation. The CCPA has already been amended several times, including through a November 2020 ballot initiative (called the California Privacy Rights Act) (“CPRA”), which will go into effect in January 2023.
Across the European Union, the General Data Protection Regulation (“GDPR”) imposes strict requirements in how we collect, transmit, process, and retain personal data, including, among other things, in certain circumstances a requirement for prompt notification of data breaches to supervisory authorities and/or to data subjects, with the risk of significant fines for non-compliance. Additionally, after a July 2020 decision from the Court of Justice of the European Union, European regulators are requiring additional safeguards to facilitate the transfer of personal information from the European Union to the United States and other certain jurisdictions.
Several other countries such as China, Russia, and Brazil have passed, and other countries are considering passing, laws that meaningfully expand the compliance requirements around confidential, personal, and/or sensitive data that we may have access to or process in the course of our business. In China and Russia, privacy and security laws may require a copy of personal data relating to citizens to be maintained on local servers and impose additional data transfer restrictions. Brazil’s Lei Geral de Proteção de Dados (“LGPD”) increases compliance requirements related to privacy, data protection, and information security for businesses that are located or do business within Brazil. Although the LGPD shares similarities with the GDPR, it also contains a number of unique features, including specific legal bases not found in the GDPR that allow an organization to process personal data and requirements for the role of a data protection officer. In these countries and elsewhere, the laws applicable to data privacy and security may require changes to business practices or additional investment for compliance purposes.
9

Table of Contents
Environmental Laws and Regulations
Our operations and properties are subject to laws and regulations relating to environmental protection, including those governing air emissions, water discharges and waste management, and workplace health and safety. For a discussion of the environmental laws and regulations that our operations, products, and services are subject to and other environmental contingencies, please refer to Note 16 to the consolidated financial statements included in this Annual Report. For a discussion of risks related to compliance with environmental and health and safety laws and risks related to past or future releases of, or exposures to, hazardous substances, please refer to “Item 1A. Risk Factors.”
Export/Import Compliance
We are required to comply with various U.S. export/import control and economic sanctions laws, such as:
the International Traffic in Arms Regulations administered by the U.S. Department of State, Directorate of Defense Trade Controls, which, among other things, impose license requirements on the export from the United States of defense articles and defense services listed on the United States Munitions List;
the Export Administration Regulations administered by the U.S. Department of Commerce, Bureau of Industry and Security, which, among other things, impose licensing requirements on the export, in-country transfer, and re-export of certain dual-use goods, technology, and software (which are items that have both commercial and military or proliferation applications);
the regulations administered by the U.S. Department of Treasury, Office of Foreign Assets Control, which implement economic sanctions imposed against designated countries, governments, and persons based on United States foreign policy and national security considerations; and
the import regulations administered by U.S. Customs and Border Protection.
Other nations’ governments have implemented similar export/import control and economic sanction regulations, which may affect our operations or transactions subject to their jurisdictions. For a discussion of risks related to export/import control and economic sanctions laws, please refer to “Item 1A. Risk Factors.”
International Operations
Our products and services are available in markets worldwide, and our principal markets outside the United States are in Europe and Asia. We also have operations around the world, and this geographic diversity allows us to draw on the skills of a worldwide workforce, provides greater stability to our operations, allows us to drive economies of scale, provides revenue streams that may help offset economic trends that are specific to individual economies, and offers us an opportunity to access new markets for products. In addition, we believe that our future growth depends in part on our ability to continue developing products and sales models that successfully target high-growth markets.
The manner in which our products and services are sold outside the United States differs by business and by region. Most of our sales in non-U.S. markets are made by our subsidiaries located outside the United States, though we also sell directly from the United States into non-U.S. markets through various representatives and distributors and, in some cases, directly. In countries with low sales volumes, we generally sell through representatives and distributors.
Available Information
We maintain an internet website at www.fortive.com where we make available free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after filing such material with, or furnishing such material to, the SEC. Our internet website and the information contained on, or linked from, that website are not incorporated by reference into this Form 10-K.
ITEM 1A. RISK FACTORS
You should carefully consider the risks and uncertainties described below, together with the information included elsewhere in this Annual Report on Form 10-K and other documents we file with the SEC. The risks and uncertainties described below are those that we have identified as material, but are not the only risks and uncertainties facing us. Our business is also subject to general risks and uncertainties that affect many other companies, such as market conditions, economic conditions, geopolitical events, changes in laws, regulations, or accounting rules, fluctuations in interest rates, terrorism, wars or conflicts, major health concerns, natural disasters, or other disruptions of expected business conditions. Additional risks and uncertainties not currently known to us or that we currently believe are immaterial also may impair our business, including our results of operations, liquidity, and financial condition.
10

Table of Contents
Risk Related to Our Business Operations
The effect of the COVID-19 pandemic on our global operations and the operations of our customers, suppliers, and vendors is continuing to have a material, adverse impact on our business and results of operations.
Our global operations expose us broadly to the COVID-19 pandemic. In particular, continued efforts to mitigate the spread of the virus have caused us, our suppliers, and customers to reduce commercial activities and utilization of facilities and manufacturing sites, adversely impacting demand for our products and services, our ability to source required materials and components, and our ability to manufacture, sell, and service our products. In addition, implementation of measures to help control the spread of the virus, including internal work-from-home policies to protect the health of our employees and community, travel restrictions, social distancing measures, and re-opening restrictions have negatively impacted our collaboration efforts with our global colleagues, customers, vendors, and service providers, and increased the risk and cost of protecting against cyber attacks. While we continue to implement global and local response teams, incremental cost reduction efforts, and business continuity efforts internally and with our customers, suppliers, and vendors, the duration and extent of the operational and financial impact of the COVID-19 pandemic remains highly uncertain.
The degree to which COVID-19 impacts us going forward will depend on future developments that are highly uncertain and therefore cannot be predicted, including, but not limited to, the duration and spread of the pandemic, its severity, or the actions taken to contain the spread and impact of COVID-19, the general availability, effectiveness, and distribution of any vaccine, and how quickly and to what extent normal economic, market, and operating conditions resume. Even after the COVID-19 pandemic has subsided as a public health matter, we may experience material adverse impacts to our business as a result of its adverse impact on the global economy, in-person collaboration efforts, and consumer confidence.
Conditions in the global economy, the markets we serve and the financial markets may adversely affect our business and financial statements.
Our business is sensitive to general economic conditions. Slower global economic growth, actual or anticipated default on sovereign debt, changes in global trade policies, volatility in the currency and credit markets, high levels of unemployment and underemployment, reduced levels of capital expenditures, changes in government fiscal and monetary policies, government deficit reduction and budget negotiation dynamics, sequestration, other austerity measures, political and social instability, natural disasters, terrorist attacks, and other challenges that affect the global economy adversely affect us and our distributors, customers, and suppliers, including having the effect of:
reducing demand for our products, software, and services, limiting the financing available to our customers and suppliers, increasing order cancellations, and resulting in longer sales cycles and slower adoption of new technologies;
increasing the difficulty in collecting accounts receivable and the risk of excess and obsolete inventories;
increasing price competition in our served markets;
supply interruptions, which could disrupt our ability to produce our products;
increasing the risk of impairment of goodwill and other long-lived assets, and the risk that we may not be able to fully recover the value of other assets such as real estate and tax assets; and
increasing the risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations which, in addition to increasing the risks identified above, could result in preference actions against us.
In addition, adverse general economic conditions may lead to instability in U.S. and global capital and credit markets, including market disruptions, limited liquidity, and interest rate volatility. If we are unable to access capital and credit markets on terms that are acceptable to us or our lenders are unable to provide financing in accordance with their contractual obligations, we may not be able to make certain investments or acquisitions or fully execute our business plans and strategies. Furthermore, our suppliers and customers are also dependent upon the capital and credit markets. Limitations on the ability of customers, suppliers, or financial counterparties to access credit at interest rates and on terms that are acceptable to them could lead to insolvencies of key suppliers and customers, limit or prevent customers from obtaining credit to finance purchases of our products and services, and cause delays in the delivery of key products from suppliers.
If growth in the global economy or in any of the markets we serve slows for a significant period, if there is significant deterioration in the global economy or such markets, if there is instability in global capital and credit markets, or if improvements in the global economy do not benefit the markets we serve, our business and financial statements could be adversely affected.
11

Table of Contents
Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated, or experience cyclicality.
Our growth depends in part on the growth of the markets which we serve, and visibility into our markets is limited (particularly for markets into which we sell through distribution). Our quarterly sales and profits depend substantially on the volume and timing of orders received during the fiscal quarter, which are difficult to forecast. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which could adversely affect our financial statements. Certain of our businesses operate in industries that may experience periodic, cyclical downturns. In addition, in certain of our businesses, demand depends on customers’ capital spending budgets, and product and economic cycles can affect the spending decisions of these entities. Demand for our products and services is also sensitive to changes in customer order patterns, which may be affected by announced price changes, changes in incentive programs, new product introductions, and customer inventory levels. Any of these factors could adversely affect our growth and results of operations in any given period.
We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce prices for our products and services.
Many of our businesses operate in industries that are intensely competitive and have been subject to consolidation. Because of the range of the products and services we sell and the variety of markets we serve, we encounter a wide variety of competitors; please see the section entitled “Business-Competition” for additional details. In order to compete effectively, we must retain longstanding relationships with major customers and continue to grow our business by establishing relationships with new customers, continually developing new or enhanced products and services to maintain and expand our brand recognition and leadership position in various product and service categories, and penetrating new markets, including high-growth markets. Our failure to compete effectively and/or pricing pressures resulting from competition may adversely impact our financial statements, and our expansion into new markets may result in greater-than-expected risks, liabilities and expenses.
Our growth depends in part on the timely development and commercialization and customer acceptance of new and enhanced products and services based on technological innovation.
We generally sell our products and services in industries that are characterized by rapid technological changes, frequent new product introductions and changing industry standards. If we do not develop innovative new and enhanced products and services on a timely basis, our offerings will become obsolete over time and our competitive position and financial statements will suffer. Our success will depend on several factors, including our ability to:
correctly identify customer needs and preferences and predict future needs and preferences;
allocate our research and development funding to products and services with higher growth prospects;
anticipate and respond to our competitors’ development of new products and services and technological innovations;
differentiate our offerings from our competitors’ offerings and avoid commoditization;
innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that may have valuable applications in our served markets;
obtain adequate intellectual property rights with respect to key technologies before our competitors do;
successfully commercialize new technologies in a timely manner, price them competitively, and cost-effectively manufacture and deliver sufficient volumes of new products of appropriate quality on time; and
stimulate customer demand for and convince customers to adopt new technologies.
In addition, if we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products and services that do not lead to significant revenue, which would adversely affect our profitability. Even if we successfully innovate and develop new and enhanced products and services, we may incur substantial costs in doing so, and our profitability may suffer.
If we are unable to recruit and retain key employees, our business may be harmed.
Much of our future success and our ability to realize the benefit of our acquisitions and execute our portfolio strategy depends on our ability to attract and retain key employees, including our senior management. In particular, the markets for highly skilled employees and leaders in the technology and healthcare industries are extremely competitive. Our brand, our culture, our ability to provide competitive compensation, our locations of operations, and our reputation are important to our ability to recruit and retain key employees in these competitive markets. If we are not competitive or successful in our recruiting efforts, if we cannot attract or retain key employees, or if we do not adequately ensure effective succession planning or transfer of knowledge for our key employees, our ability to deliver and execute on our operational, development, or portfolio strategies would be adversely affected.
12

Table of Contents
A significant disruption in, or breach in security of, our information technology systems could adversely affect our business.
We rely on information technology systems, some of which are managed by third parties and some of which are managed on a decentralized, independent basis by our operating companies, to process, transmit, and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers, and other business partners), and to manage or support a variety of critical business processes and activities. These systems may be damaged, disrupted, or shut down due to attacks by computer hackers, nation states, cyber-criminals, computer viruses, employee error or malfeasance, power outages, hardware failures, telecommunication or utility failures, catastrophes, or other unforeseen events, and in any such circumstances our system redundancy and other disaster recovery planning may be ineffective or inadequate. In addition, security breaches of our systems (or the systems of our customers, suppliers or other business partners) could result in the misappropriation, destruction, or unauthorized disclosure of confidential information or personal data belonging to us or to our employees, partners, customers, or suppliers. Like many multinational corporations, our information technology systems have been subject to computer viruses, malicious codes, unauthorized access, and other cyber-attacks and we expect to be subject to similar incidents in the future as such attacks become more sophisticated and frequent. Any of the attacks, breaches, or other disruptions or damage described above can interrupt our operations, delay production and shipments, result in theft of our and our customers’ intellectual property and trade secrets, damage customer and business partner relationships and our reputation, or result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws, and increased costs for security and remediation, each of which could adversely affect our business and financial statements.
Defects and unanticipated use or inadequate disclosure with respect to our products (including software) or services could adversely affect our business, reputation, and financial statements.
Manufacturing or design defects impacting safety, cybersecurity, or quality issues (or the perception of such issues) for our products and services can lead to personal injury, death, property damage, data loss, or other damages. These events could lead to recalls or safety or other public alerts, result in product or service downtime or the temporary or permanent removal of a product or service from the market and result in product liability or similar claims being brought against us. Recalls, downtime, removals, and product liability and similar claims (regardless of their validity or ultimate outcome) can result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products and services.
Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns, or inventory levels of, key distributors and other channel partners could adversely affect our financial statements.
Certain of our businesses sell a significant amount of their products to key distributors and other channel partners that have valuable relationships with customers and end-users. Some of these distributors and other partners also sell our competitors’ products or compete with us directly, and if they favor competing products for any reason they may fail to market our products effectively. Adverse changes in our relationships with these distributors and other partners, or adverse developments in their financial condition, performance, or purchasing patterns, could adversely affect our financial statements. The levels of inventory maintained by our distributors and other channel partners, and changes in those levels, can also significantly impact our results of operations in any given period. In addition, the consolidation of distributors and customers in certain of our served industries could adversely impact our profitability.
Our financial results are subject to fluctuations in the cost and availability of commodities or components that we use in our operations.
As discussed in the section entitled “Business-Materials,” our manufacturing and other operations employ a wide variety of components, raw materials, and other commodities. Prices for and availability of these components, raw materials, and other commodities have fluctuated significantly in the past. Any sustained interruption in the supply of these items, including as a result of contractual disputes with suppliers or vendors, could adversely affect our business. In addition, due to the highly competitive nature of the industries that we serve, the cost-containment efforts of our customers, and the terms of certain contracts we are party to, if commodity or component prices rise we may be unable to pass along cost increases through higher prices. If we are unable to fully recover higher commodity or component costs through price increases or offset these increases through cost reductions, or if there is a time delay between the increase in costs and our ability to recover or offset these costs, we could experience lower margins and profitability and our financial statements could be adversely affected.
13

Table of Contents
If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our profitability may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components, and services could cause production interruptions, delays, and inefficiencies.
We purchase materials, components, and equipment from third parties for use in our manufacturing operations. Our income could be adversely impacted if we are unable to adjust our purchases to reflect changes in customer demand and market fluctuations, including those caused by seasonality or cyclicality. During a market upturn, suppliers may extend lead times, limit supplies, or increase prices. If we cannot purchase sufficient products at competitive prices and quality and on a timely enough basis to meet increasing demand, we may not be able to satisfy market demand, product shipments may be delayed, our costs may increase, or we may breach our contractual commitments and incur liabilities. Conversely, in order to secure supplies for the production of products, we sometimes enter into noncancelable purchase commitments with vendors, which could impact our ability to adjust our inventory to reflect declining market demands. If demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to incur additional charges and our profitability may suffer.
In addition, some of our businesses purchase certain requirements from sole or limited source suppliers for reasons of quality assurance, cost effectiveness, availability, contractual obligations or uniqueness of design. If these or other suppliers encounter financial, operating, quality, or other difficulties or if our relationship with them changes, including as a result of contractual disputes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could also be disrupted by supplier capacity constraints, operational or quality issues, bankruptcy or exiting of the business for other reasons, decreased availability of key raw materials or commodities, and external events such as natural disasters, pandemic health issues, war, terrorist actions, governmental actions, and legislative or regulatory changes. Any of these factors could result in production interruptions, delays, extended lead times, and inefficiencies.
Because we cannot always immediately adapt our production capacity and related cost structures to changing market conditions, our manufacturing capacity may at times exceed or fall short of our production requirements. Any or all of these problems could result in the loss of customers, provide an opportunity for competing products to gain market acceptance, and otherwise adversely affect our profitability.
Our restructuring actions could have long-term adverse effects on our business.
In recent years, we have implemented multiple, significant restructuring activities across our businesses to adjust our cost structure, and we may engage in similar restructuring activities in the future. These restructuring activities and our regular ongoing cost reduction activities (including in connection with the integration of acquired businesses) reduce our available talent, assets, and other resources and could slow improvements in our products and services, adversely affect our ability to respond to customers and limit our ability to increase production quickly if demand for our products increases. In addition, delays in implementing planned restructuring activities or other productivity improvements, unexpected costs, or failure to meet targeted improvements may diminish the operational or financial benefits we realize from such actions. Any of the circumstances described above could adversely impact our business and financial statements.
Work stoppages, works council campaigns, and other labor disputes could adversely impact our productivity and results of operations.
We have various non-U.S. collective labor arrangements. We are subject to potential work stoppages, works council campaigns, and other labor disputes, any of which could adversely impact our productivity, results of operations, and reputation.
If we suffer loss to our facilities, supply chains, distribution systems, or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
Our facilities, supply chains, distribution systems, and information technology systems are subject to catastrophic loss due to fire, flood, earthquake, hurricane, public health crisis, war, terrorism, or other natural or man-made disasters. If any of these facilities, supply chains, or systems were to experience a catastrophic loss, it could disrupt our operations, delay production and shipments, result in defective products or services, damage customer relationships and our reputation, and result in legal exposure and large repair or replacement expenses. The third-party insurance coverage that we maintain will vary from time to time in both type and amount depending on cost, availability, and our decisions regarding risk retention, and may be unavailable or insufficient to protect us against losses.
14

Table of Contents
If we do not or cannot adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.
We own numerous patents, trademarks, copyrights, trade secrets, and other intellectual property and licenses to intellectual property owned by others, which in aggregate are important to our business. The intellectual property rights that we obtain, however, may not be sufficiently broad or otherwise may not provide us a significant competitive advantage, and patents may not be issued for pending or future patent applications owned by or licensed to us. In addition, the steps that we and our licensors have taken to maintain and protect our intellectual property may not prevent it from being challenged, invalidated, circumvented, designed-around, or becoming subject to compulsory licensing, particularly in countries where intellectual property rights are not highly developed or protected. In some circumstances, enforcement may not be available to us because an infringer has a dominant intellectual property position or for other business reasons, or countries may require compulsory licensing of our intellectual property. We also rely on nondisclosure and noncompetition agreements with employees, consultants, and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements will adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information, or that third parties will not otherwise gain access to our trade secrets or other proprietary rights. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property, and the cost of enforcing our intellectual property rights could adversely impact our competitive position and financial statements.
Third parties may claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses, or licensing expenses or be prevented from selling products or services.
From time to time, we receive notices from third parties alleging intellectual property infringement or misappropriation. Any dispute or litigation regarding intellectual property could be costly and time-consuming due to the complexity of many of our technologies and the uncertainty of intellectual property litigation. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response to a claim of infringement or misappropriation. In addition, as a result of such claims of infringement or misappropriation, we could lose our rights to critical technology, be unable to license critical technology or sell critical products and services, be required to pay substantial damages or license fees with respect to the infringed rights, or be required to redesign our products at substantial cost, any of which could adversely impact our competitive position and financial statements. Even if we successfully defend against claims of infringement or misappropriation, we may incur significant costs and diversion of management attention and resources, which could adversely affect our financial statements.
We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our financial statements.
We are subject to a variety of litigation and other legal and regulatory proceedings incidental to our business (or the business operations of previously owned entities), including claims for damages arising out of the use of products or services and claims relating to intellectual property matters, employment matters, appropriate classification of franchisee relationship, tax matters, commercial disputes, disputes with our supplier or vendors, competition and sales and trading practices, environmental matters, personal injury, insurance coverage, and acquisition or divestiture-related matters, as well as regulatory investigations or enforcement. We may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties, or indemnities provided in connection with, divested businesses. These lawsuits may include claims for compensatory damages, punitive and consequential damages, and/or injunctive relief. The defense of these lawsuits may divert our management’s attention, we may incur significant expenses in defending these lawsuits, we may experience disruption in supply or sales, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial statements. Moreover, any insurance or indemnification rights that we may have may be insufficient or unavailable to protect us against such losses. In addition, developments in proceedings in any given period may require us to adjust the loss contingency estimates that we have recorded in our financial statements, record estimates for liabilities or assets that we were previously unable to estimate, or pay cash settlements or judgments. Any of these developments could adversely affect our financial statements in any particular period. We cannot assure you that our liabilities in connection with litigation and other legal and regulatory proceedings will not exceed our estimates or adversely affect our financial statements and reputation.
Risk Related to our International Operations
International economic, political, legal, compliance, and business factors could negatively affect our financial statements.
In 2020, approximately 47% of our sales were derived from customers outside the United States. Our principal markets outside the United States are in Europe and Asia. In addition, many of our manufacturing operations, suppliers, and employees are
15

Table of Contents
located outside the United States. Since our growth strategy depends in part on our ability to further penetrate markets outside the United States and increase the localization of our products and services, we expect to continue to increase our sales and presence outside the United States, particularly in high-growth markets, such as Eastern Europe, the Middle East, Africa, Latin America, and Asia. Our international business, including our business in high-growth markets outside the United States, is subject to risks that are customarily encountered in non-U.S. operations, as well as increased risks due to significant uncertainties related to political and economic changes, including:
interruption in the transportation of materials to us and finished goods to our customers;
differences in terms of sale, including payment terms;
local product preferences and product requirements;
changes in a country’s or region’s political or economic conditions, including changes in relationship with the United States, particularly with respect to China;
trade protection measures, increased trade barriers, imposition of significant tariffs on imports or exports, embargoes, and import or export restrictions and requirements;
new conditions to, and possible restrictions of, existing free trade agreements;
epidemics, such as the coronavirus outbreak, that adversely impact travel, production, or demand;
unexpected changes in laws or regulatory requirements, including negative changes in tax laws in the U.S. and in the countries in which we manufacture or sell our products;
the impact of the U.K.’s exit from the E.U. (Brexit) on the Company’s business operations in the U.K. and Europe, including the effects of the Trade and Cooperation Agreement between the European Union, the European Atomic Energy Community, and the United Kingdom signed on December 30, 2020;
limitations on ownership and on repatriation of earnings and cash;
the potential for nationalization of enterprises;
limitations on legal rights and our ability to enforce such rights;
difficulty in staffing and managing widespread operations;
differing labor regulations;
difficulties in implementing restructuring actions on a timely or comprehensive basis; and
differing protection of intellectual property.
Any of these risks could negatively affect our financial statements and growth.
Trade relations between China and the United States could have a material adverse effect on our business and financial statements.
We have experienced growth in various end markets in China. During 2020, year-over-year sales from existing businesses grew slightly in China, and sales in China accounted for approximately 12% of our total sales for the year. In addition, we have numerous facilities in China, many of which serve multiple businesses and are used for multiple purposes.
There continues to be significant uncertainty about the future relationship between the United States and China, including with respect to trade policies, treaties, government regulations, and tariffs. In particular, there continues to be uncertainty about U.S. foreign trade policy with respect to China, including any changes to the trade policies that may be adopted by the new administration. Any increased trade barriers or restrictions on global trade, especially trade with China, could adversely impact our business and financial statements.
Foreign currency exchange rates may adversely affect our financial statements.
Sales and purchases in currencies other than the U.S. dollar expose us to fluctuations in foreign currencies relative to the U.S. dollar and may adversely affect our financial statements. Increased strength of the U.S. dollar increases the effective price of our products sold in U.S. dollars into other countries, which may require us to lower our prices or adversely affect sales to the extent we do not increase local currency prices. Decreased strength of the U.S. dollar could adversely affect the cost of materials, products and services we purchase overseas. Sales and expenses of our non-U.S. businesses are also translated into U.S. dollars for reporting purposes and the strengthening or weakening of the U.S. dollar could result in unfavorable translation effects. In addition, certain of our businesses transact in a currency other than the business’ functional currency, and movements in the transaction currency relative to the functional currency could also result in unfavorable exchange rate effects. We also face exchange rate risk from our investments in subsidiaries owned and operated in foreign countries.
16

Table of Contents
Risk Related to Our Acquisitions, Investments, and Dispositions
Any inability to consummate acquisitions at our anticipated rate and at appropriate prices could negatively impact our growth rate and stock price.
Our ability to grow revenues, earnings, and cash flow at or above our anticipated rates depends in part upon our ability to identify and successfully acquire and integrate businesses at appropriate prices and realize anticipated synergies. We may not be able to consummate acquisitions at rates anticipated, which could adversely impact our growth rate and our stock price. Promising acquisitions are difficult to identify and complete for a number of reasons, including high valuations, competition among prospective buyers, the availability of affordable funding in the capital markets and the need to satisfy applicable closing conditions and obtain antitrust and other regulatory approvals on acceptable terms. In addition, competition for acquisitions may result in higher purchase prices. Changes in accounting or regulatory requirements or instability in the credit markets could also adversely impact our ability to consummate acquisitions.
Our acquisition of businesses, joint ventures, and strategic relationships could negatively impact our financial statements.
As part of our business strategy we acquire businesses and enter other strategic relationships in the ordinary course, some of which may be material; please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) for additional details. These acquisitions and strategic relationships involve a number of financial, accounting, managerial, operational, legal, compliance, and other risks and challenges, including the following, any of which could adversely affect our financial statements:
any acquired business, technology, service, or product could under-perform relative to our expectations and the price that we paid for it, or not perform in accordance with our anticipated timetable;
we may incur or assume significant debt in connection with our acquisitions or strategic relationships;
acquisitions or strategic relationships could cause our financial results to differ from our own or the investment community’s expectations in any given period, or over the long-term;
pre-closing and post-closing earnings charges could adversely impact operating results in any given period, and the impact may be substantially different from period to period;
acquisitions or strategic relationships could create demands on our management, operational resources, and financial and internal control systems that we are unable to effectively address;
we could experience difficulty in integrating personnel, operations, and financial and other controls and systems and retaining key employees and customers;
we may be unable to achieve cost savings or other synergies anticipated in connection with an acquisition or strategic relationship;
we may assume by acquisition or strategic relationship unknown liabilities, known contingent liabilities that become realized, known liabilities that prove greater than anticipated, internal control deficiencies, or exposure to regulatory sanctions resulting from the acquired company’s activities and the realization of any of these liabilities or deficiencies may increase our expenses, adversely affect our financial position, or cause us to fail to meet our public financial reporting obligations;
in connection with acquisitions, we may enter into post-closing financial arrangements such as purchase price adjustments, earn-out obligations, and indemnification obligations, which may have unpredictable financial results;
in connection with acquisitions, we have recorded significant goodwill and other intangible assets on our balance sheet and if we are not able to realize the value of these assets, we may be required to incur charges relating to the impairment of these assets; and
we may have interests that diverge from those of strategic partners and we may not be able to direct the management and operations of the strategic relationship in the manner we believe is most appropriate, exposing us to additional risk.
The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against certain liabilities related to the operation of the company before we acquired it. In most of these agreements, however, the liability of the former owners is limited and certain former owners may be unable to meet their indemnification responsibilities. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result we may face
unexpected liabilities that adversely affect our financial statements.
17

Table of Contents
Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we have sold could adversely affect our financial statements.
We continually assess the strategic fit of our existing businesses and may divest or otherwise dispose of businesses that are deemed not to fit with our strategic plan or are not achieving the desired return on investment. For example, in 2018, we split-off most of our automation and specialty platform in a Reverse Morris Trust transaction with Altra Industrial Motion Corp.. and, in 2020, we spun-off our former Industrial Technologies segment. These transactions pose risks and challenges that could negatively impact our business. For example, when we decide to sell or otherwise dispose of a business or assets, we may be unable to do so on satisfactory terms within our anticipated timeframe or at all, and even after reaching a definitive agreement to sell or dispose a business the sale is typically subject to satisfaction of pre-closing conditions which may not become satisfied. In addition, divestitures or other dispositions may dilute our earnings per share, have other adverse financial and accounting impacts and distract management, and disputes may arise with buyers. In addition, we have retained responsibility for and/or have agreed to indemnify buyers against some known and unknown contingent liabilities related to a number of businesses we have sold or disposed. The resolution of these contingencies has not had a material effect on our financial statements but we cannot be certain that this favorable pattern will continue.
Potential indemnification liabilities to Vontier pursuant to the separation agreement could materially and adversely affect our businesses, financial condition, results of operations, and cash flows.
We entered into a separation and distribution agreement and related agreements with Vontier to govern the separation and distribution of Vontier and the relationship between the two companies going forward. These agreements provide for specific indemnity and liability obligations of each party and could lead to disputes between us. If we are required to indemnify Vontier under the circumstances set forth in these agreements, we may be subject to substantial liabilities. In addition, with respect to the liabilities for which Vontier has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against Vontier will be sufficient to protect us against the full amount of the liabilities, or that Vontier will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our businesses, financial condition, results of operations, and cash flows.
Risk Related to Regulatory and Compliance Matters
Changes in industry standards and governmental regulations may reduce demand for our products or services or increase our expenses.
We compete in markets in which we and our customers must comply with supranational, federal, state, local, and other jurisdictional regulations, such as regulations governing health and safety, the environment, and electronic communications, and market standardizations. We develop, configure, and market our products and services to meet customer needs created by these regulations and standards. These regulations and standards are complex, change frequently, have tended to become more stringent over time, and may be inconsistent across jurisdictions. Any significant change or delay in implementation in any of these regulations or standards (or in the interpretation, application, or enforcement thereof) could reduce or delay demand for our products and services, increase our costs of producing or delay the introduction of new or modified products and services, or could restrict our existing activities, products, and services. In addition, in certain of our markets our growth depends in part upon the introduction of new regulations or implementation of industry standards on the timeline we expect. In these markets, the delay or failure of governmental and other entities to adopt or enforce new regulations or industry standards, or the adoption of new regulations or industry standards which our products and services are not positioned to address, could adversely affect demand. In addition, regulatory deadlines or industry standard implementation timelines may result in substantially different levels of demand for our products and services from period to period.
Our reputation, ability to do business, and financial statements may be impaired by improper conduct by any of our employees, agents, or business partners.
We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents, or business partners of ours (or of businesses we acquire or partner with) that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks, and false claims, sales and marketing practices, conflicts of interest, competition, export and import compliance, money laundering, and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In
18

Table of Contents
addition, though we rely on our suppliers to adhere to our supplier standards of conduct, material violations of such standards of conduct could occur that could have a material effect on our financial statements.
Our operations, products, and services expose us to the risk of environmental, health, and safety liabilities, costs, and violations that could adversely affect our reputation and financial statements.
Our operations, products and services are subject to environmental laws and regulations, which impose limitations on the discharge of pollutants into the environment and establish standards for the use, generation, treatment, storage, and disposal of hazardous and non-hazardous wastes. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations. In addition, some of our operations require the controlled use of hazardous or energetic materials in the development, manufacturing, or servicing of our products. We cannot assure you that our environmental, health, and safety compliance program has been or will at all times be effective. Failure to comply with any of these laws could result in civil and criminal, monetary and non-monetary penalties and damage to our reputation. In addition, we cannot provide assurance that our costs of complying with current or future environmental protection and health and safety laws will not exceed our estimates or adversely affect our financial statements. Moreover, any accident that results in significant personal injury or property damage, whether occurring during development, manufacturing, servicing, use, or storage of our products, may result in significant production interruption, delays, or claims for substantial damages caused by personal injuries or property damage, harm to our reputation, and reduction in morale among our employees, any of which may adversely and materially affect our results of operations.
In addition, we may incur costs related to remedial efforts or alleged environmental damage associated with past or current waste disposal practices or other hazardous materials handling practices. We are also from time to time party to personal injury or other claims brought by private parties alleging injury due to the presence of or exposure to hazardous substances. We may also become subject to additional remedial, compliance or personal injury costs due to future events such as changes in existing laws or regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes in the conduct of our operations and changes in accounting rules. For additional information regarding these risks, please refer to Note 16 to the consolidated financial statements. We cannot assure you that our liabilities arising from past or future releases of, or exposures to, hazardous substances will not exceed our estimates or adversely affect our reputation and financial statements or that we will not be subject to additional claims for personal injury or remediation in the future based on our past, present or future business activities.
Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our financial statements and reputation.
In addition to the environmental, health, safety, anti-corruption, and other regulations noted above, our businesses are subject to extensive regulation by U.S. and non-U.S. governmental and self-regulatory entities at the supranational, federal, state, local, and other jurisdictional levels, including the following:
we are required to comply with various import laws and export control and economic sanctions laws, which may affect our transactions with certain customers, business partners, and other persons and dealings between our employees and subsidiaries. In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services, and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt our supply of imported inventory;
we also have agreements to sell products and services to government entities and are subject to various statutes and regulations that apply to companies doing business with government entities. The laws governing government contracts differ from the laws governing private contracts. For example, many government contracts contain pricing and other terms and conditions that are not applicable to private contracts. Our agreements with government entities may be subject to termination, reduction, or modification at the convenience of the government or in the event of changes in government requirements, reductions in federal spending and other factors, and we may underestimate our costs of performing under the contract. Government contracts that have been awarded to us following a bid process could become the subject of a bid protest by a losing bidder, which could result in loss of the contract. We are also subject to investigation and audit for compliance with the requirements governing government contracts;
we are also required to comply with increasingly complex and changing data privacy regulations in multiple jurisdictions that regulate the collection, use, protection, and transfer of personal data, including the transfer of personal data between or among countries. In particular, the General Data Protection Regulation became effective in the European Union in May 2018 and the California Consumer Privacy Act became effective in January 2020. We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations. An adverse outcome under any such investigation or audit could subject us to fines
19

Table of Contents
or other penalties. That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position;
certain of our products are medical devices that are subject to regulation by the U.S. FDA, by other federal and state governmental agencies, by comparable agencies of other countries and regions, and by certain accrediting bodies. To varying degrees, these regulators require us to comply with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and post-marketing surveillance of our products; and
we are also required to comply with ever changing labor and employment laws and regulations in multiple jurisdictions. These changes could negatively impact our business or financial position.
These are not the only regulations that our businesses must comply with. The regulations we are subject to have tended to become more stringent over time and may be inconsistent across jurisdictions. We, our representatives, and the industries in which we operate may at times be under review and/or investigation by regulatory authorities. Failure to comply (or any alleged or perceived failure to comply) with the regulations referenced above or any other regulations could result in civil and criminal, monetary and non-monetary penalties, and any such failure or alleged failure (or becoming subject to a regulatory enforcement investigation) could also damage our reputation, disrupt our business, limit our ability to manufacture, import, export, and sell products and services, result in loss of customers and disbarment from selling to certain federal agencies and cause us to incur significant legal and investigatory fees. Compliance with these and other regulations may also affect our returns on investment, require us to incur significant expenses, or modify our business model or impair our flexibility in modifying product, marketing, pricing, or other strategies for growing our business. Our products and operations are also often subject to the rules of industrial standards bodies such as the International Standards Organization, and failure to comply with these rules could result in withdrawal of certifications needed to sell our products and services and otherwise adversely impact our financial statements.
For additional information regarding these risks, please refer to the section entitled “Business-Regulatory Matters.”
Risk Related to Our Tax and Accounting Matters
Changes in our effective tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods.
We are subject to income and transaction taxes in the United States and in multiple foreign jurisdictions.
A change in the tax laws of the jurisdictions where we operate, including any increase in U.S. corporate income tax rates, could result in a material increase in our tax expense. In addition, foreign remittance taxes have not been provided for on undistributed earnings of certain of our non-U.S. subsidiaries to the extent such earnings are considered to be indefinitely reinvested in the operations of those subsidiaries. If our intentions regarding reinvestment of such earnings change, then our income tax expense could increase. On December 22, 2017, the U.S. enacted comprehensive tax reform commonly referred to as the Tax Cut and Jobs Act (“TCJA”). The TCJA represents one of the most significant overhauls to the U.S. federal tax code since 1986 according to the SEC. The TCJA includes numerous provisions that affect businesses and introduces changes that impact U.S. corporate tax rates, business-related exclusions, deductions, and credits. Further guidance, regulations, and technical corrections pertaining to TCJA continue to be issued by the tax authorities, some of which may have retroactive application. We will continue to assess such new guidance, regulations, and corrections as they are issued. However, there can be no assurance that the retroactive applications of such new guidance, regulations, or corrections issued by the tax authorities will not result in revisions to our prior interpretation of the corresponding provisions of TCJA that may have a material adverse effect on our financial statements.
Further changes in the tax laws of foreign jurisdictions could arise as a result of the base erosion and profit shifting project undertaken by the Organisation for Economic Co-operation and Development (“OECD”), which represents a coalition of member countries. The OECD has issued significant global tax policy changes that include both expanded reporting as well as technical global tax policy changes. Many countries in which we operate have implemented tax law and administrative changes that align with many aspects of the OECD policy guidelines. The breadth of this project may impact all multinational businesses by potentially redefining jurisdictional taxation rights, and could materially impact the law for transfer pricing and permanent establishment taxation. We have taken measures to address the requirements of these changes in global tax policy. The Company will continue to monitor and evaluate the impact of these new OECD developments.
Changes in relation to international tax reform could increase uncertainty in the corporate tax area and may adversely affect our provision for income taxes. In addition, the amount of income taxes we pay is subject to ongoing audits by U.S. federal, state, and local tax authorities and by non-U.S. tax authorities. Due to the potential for changes to tax laws (or changes to the interpretation thereof) and the ambiguity of tax laws, the subjectivity of factual interpretations, the complexity of our intercompany arrangements and other factors, our estimates of income tax liabilities may differ from actual payments or
20

Table of Contents
assessments. If these audits result in payments or assessments different from our reserves, our future results may include unfavorable adjustments to our tax liabilities and our financial statements could be adversely affected. If we determine to repatriate earnings from foreign jurisdictions that have been considered permanently reinvested under existing accounting standards, it could also increase our effective tax rate.
We could incur significant liability if the separation and distribution of Vontier is determined to be a taxable transaction.
We have received an opinion from outside tax counsel to the effect that the separation and distribution of Vontier qualifies as a transaction that is described in Sections 355(a) and 368(a)(1)(D) of the Internal Revenue Code. The opinion relies on certain facts, assumptions, representations, and undertakings from Vontier and us regarding the past and future conduct of the companies’ respective businesses and other matters. If any of these facts, assumptions, representations, or undertakings are incorrect or not satisfied, our stockholders and we may not be able to rely on the opinion of tax counsel and could be subject to significant tax liabilities. Notwithstanding the opinion of tax counsel we have received, the IRS could determine on audit that the separation and distribution are taxable if it determines that any of these facts, assumptions, representations, or undertakings are not correct or have been violated or if it disagrees with the conclusions in the opinion. If the separation and distribution of Vontier are determined to be taxable for U.S. federal income tax purposes, our stockholders that are subject to U.S. federal income tax and we could incur significant U.S. federal income tax liabilities.
Changes in U.S. GAAP could adversely affect our reported financial results and may require significant changes to our internal accounting systems and processes.
We prepare our consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”). These principles are subject to interpretation by the Financial Accounting Standards Board (“FASB”), the SEC, and various bodies formed to interpret and create appropriate accounting principles and guidance. Any new or amended standards may result in different accounting principles, which may significantly impact our reported results or could result in volatility of our financial results.
We may be required to recognize impairment charges for our goodwill and other intangible assets.
As of December 31, 2020, the net carrying value of our goodwill and other intangible assets totaled approximately $10.6 billion. In accordance with GAAP, we periodically assess these assets to determine if they are impaired. Significant negative industry or economic trends, disruptions to our business, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of our assets, changes in the structure of our business, divestitures, market capitalization declines, or increases in associated discount rates may impair our goodwill and other intangible assets. Any charges relating to such impairments would adversely affect our results of operations in the periods recognized. Refer to Note 2 and Note 7 to the consolidated financial statements for a description of our policies relating to goodwill and acquired intangibles.
Risk Related to Our Financing Activities
We have incurred a significant amount of debt, and our debt will increase further if we incur additional debt and do not retire existing debt.
As of December 31, 2020, we had approximately $4.2 billion of long-term debt, including the current portion of long-term debt, on a consolidated basis. We may also obtain additional long-term debt and lines of credit to meet future financing needs. Our debt level and related debt service obligations could have negative consequences, including:
requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which would reduce the funds we have available for other purposes, such as acquisitions;
making it more difficult for us to satisfy our obligations with respect to our debt;
placing us at a competitive disadvantage compared to our competitors that are not as highly leveraged;
limiting our ability to borrow additional funds;
reducing our flexibility in planning for or reacting to changes in our business and market conditions;
exposing us to interest rate risk since a portion of our debt obligations are at variable rates; and
resulting in an event of default if we fail to satisfy our obligations under our debt or fail to comply with the financial or restrictive covenants contained in our debt instruments, which event of default could result in all of our debt becoming immediately due and payable and could permit certain of our lenders to foreclose on our assets securing such debt.
Our ability to satisfy our obligations depends on our future operating performance and on economic, financial, competitive, and other factors beyond our control. Our business may not generate sufficient cash flow to meet these obligations. If we are unable
21

Table of Contents
to service our debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures, or research and development expenditures. We may not be able to obtain additional financing on terms acceptable to us or at all.
Additionally, the agreements governing our debt require that we maintain certain financial ratios, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, make investments, create liens, sell assets, and enter into transactions with affiliates. The covenants in our credit agreement include a debt-to-EBITDA ratio. Please refer to Note 11 to the consolidated financial statements for additional details.
Our ability to comply with these restrictions and covenants may be affected by events beyond our control. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under one of our debt instruments would trigger an event of default under other of our debt instruments.
The interest rates on our credit facilities may be impacted by the phase out of the London Interbank Offered Rate (“LIBOR”).
Pursuant to the terms of our credit facilities, the interest rate on our credit facilities may be based on LIBOR, which is in the process of being phased-out. The FCA, which regulates LIBOR, has announced that it has commitments from panel banks to continue to contribute to LIBOR through the end of 2021, but that the FCA will not use its powers to compel contributions beyond such date. Accordingly, there is considerable uncertainty regarding the publication of LIBOR beyond 2021 and it is not currently possible to determine precisely whether, or to what extent, the withdrawal and replacement of LIBOR would affect the Company; however, the implementation of alternative benchmark rates to LIBOR may have an adverse impact on the cost of our borrowings under our credit facilities.
Risk Related to Shareholder Rights
Certain provisions in our amended and restated certificate of incorporation and bylaws, and of Delaware law, may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.
Our amended and restated certificate of incorporation (“Restated Certificate of Incorporation”) and amended and restated bylaws (“Amended and Restated Bylaws”) contain, and Delaware law contains, provisions that are intended to deter coercive takeover practices and inadequate takeover bids and to encourage prospective acquirers to negotiate with the Board of Directors (the “Board”) rather than to attempt an unsolicited takeover not approved by the Board. These provisions include, among others:
the inability of our shareholders to call a special meeting;
the inability of our shareholders to act by written consent;
rules regarding how shareholders may present proposals or nominate directors for election at shareholder meetings;
the right of the Board to issue preferred stock without shareholder approval;
the ability of our directors, and not shareholders, to fill vacancies (including those resulting from an enlargement of the Board) on the Board; and
the requirement that the affirmative vote of shareholders holding at least 80% of our voting stock is required to amend our amended and restated bylaws and certain provisions in our amended and restated certificate of incorporation.
In addition, because we have not chosen to be exempt from Section 203 of the Delaware General Corporation Law (the “DGCL”), this provision could also delay or prevent a change of control that you may favor. Section 203 provides that, subject to limited exceptions, persons that acquire, or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation (an “interested stockholder”) shall not engage in any business combination with that corporation, including by merger, consolidation, or acquisitions of additional shares, for a three-year period following the date on which the person became an interested stockholder, unless (i) prior to such time, the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) the voting stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential right to tender or vote stock held by the plan); or (iii) on or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of shareholders by the affirmative vote of at least two-thirds of the outstanding voting stock of such corporation not owned by the interested stockholder.
22

Table of Contents
We believe these provisions will protect our shareholders from coercive or otherwise unfair takeover tactics by requiring potential acquirers to negotiate with the Board and by providing the Board with more time to assess any acquisition proposal. These provisions are not intended to make our company immune from takeovers. However, these provisions will apply even if the offer may be considered beneficial by some shareholders and could delay or prevent an acquisition that the Board determines is not in the best interests of our company and our shareholders. These provisions may also prevent or discourage attempts to remove and replace incumbent directors.
Our amended and restated certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, which could discourage lawsuits against us and our directors and officers.
Our amended and restated certificate of incorporation provides that unless the Board otherwise determines, the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, will be the sole and exclusive forum for any derivative action or proceeding brought on behalf of our company, any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or our shareholders, any action asserting a claim against our company or any of our directors or officers arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or bylaws, or any action asserting a claim against our company or any of our directors or officers governed by the internal affairs doctrine. This exclusive forum provision may limit the ability of our shareholders to bring a claim in a judicial forum that such shareholders find favorable for disputes with our company or our directors or officers, which may discourage such lawsuits against our company and our directors and officers. This exclusive forum provision would not apply to claims brought to enforce a duty or liability created by the Securities Act, the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.
ITEM 1B. UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 2. PROPERTIES
Our corporate headquarters is located in Everett, Washington in a facility that we own. As of December 31, 2020, our facilities included approximately 60 significant facilities, which are used for manufacturing, distribution, warehousing, research and development, general administrative, and/or sales functions. Approximately 30 of these facilities are located in the United States in over 10 states and approximately 30 are located outside the United States in over 10 countries, including Canada and countries in Asia Pacific, Europe, and Latin America. These facilities cover approximately 5 million square feet, of which approximately 3 million square feet are owned and approximately 2 million square feet are leased. Particularly outside the United States, facilities may serve more than one business segment and may be used for multiple purposes, such as administration, sales, manufacturing, warehousing, and/or distribution. The approximate number of significant facilities by business segment is: Intelligent Operating Solutions 25, Precision Technologies 25, and Advanced Healthcare Solutions 10.
We consider our facilities suitable and adequate for the purposes for which they are used and do not anticipate difficulty in renewing existing leases as they expire or in finding alternative facilities. We believe our properties and equipment have been well-maintained. Please refer to Note 10 to the consolidated financial statements for additional information with respect to our lease commitments.
ITEM 3. LEGAL PROCEEDINGS
We are, from time to time, subject to a variety of litigation and other legal and regulatory proceedings and claims incidental to our business. Based upon our experience, current information, and applicable law, we do not believe that these proceedings and claims will have a material effect on our financial position, results of operations or cash flows.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
23

Table of Contents
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Set forth below are the names, ages, positions, and experience of our executive officers as of February 26, 2021. All of our executive officers hold office at the pleasure of our Board.
NameAgePositionOfficer Since
James A. Lico55President and Chief Executive Officer2016
Barbara B. Hulit54Senior Vice President2016
Charles E. McLaughlin59Senior Vice President – Chief Financial Officer2016
Patrick K. Murphy59Senior Vice President2016
William W. Pringle53Senior Vice President2016
Jonathan L. Schwarz49
Senior Vice President – Corporate Development
2016
Edward R. Simmons47Senior Vice President – Strategy 2021
Peter C. Underwood51Senior Vice President – General Counsel2016
Stacey A. Walker50Senior Vice President – Human Resources2016
James A. Lico has served as Chief Executive Officer and President, as well as a member of the Board since July 2016. Prior to July 2016, Mr. Lico served in leadership positions in a variety of different functions and businesses at Danaher after joining Danaher in 1996, including as Executive Vice President from 2005 to 2016.
Barbara B. Hulit has served as a Senior Vice President since July 2016. Prior to July 2016, Ms. Hulit served as Senior Vice President-Danaher Business System Office for Danaher from January 2013 to July 2016 and as President and Group Executive of Fluke Corporation from May 2005 to January 2013. Prior to joining Danaher, Ms. Hulit was a partner at The Boston Consulting Group, a global management consulting firm.
Charles E. McLaughlin has served as Senior Vice President, Chief Financial Officer since July 2016. Prior to July 2016, Mr. McLaughlin served as Senior Vice President-Diagnostics Group CFO for Danaher’s Diagnostics business from May 2012 to July 2016, and as Senior Vice President-Chief Financial Officer of Danaher’s Beckman Coulter business from July 2011 to July 2016.
Patrick K. Murphy has served as a Senior Vice President of Fortive since July 2016. Prior to July 2016, Mr. Murphy served as a Group President of Danaher after joining Danaher in March 2014 until July 2016. Prior to joining Danaher, he served as CEO of Nidec Motor Corporation and President of the ACIM (Appliance, Commercial, and Industrial Motor) Business Unit of Nidec Corporation, a manufacturer of commercial, industrial, and appliance motors and controls, from 2010 until October 2013.
William W. Pringle who has served as a Senior Vice President of Fortive since July 2016 will resign effective March 12, 2021. Prior to July 2016, Mr. Pringle served as Senior Vice President-Fluke and Qualitrol for Danaher from October 2015 to July 2016 and as President of Danaher’s Fluke business from July 2013 to July 2016, after serving as President-Fluke Industrial Group from May 2012 to July 2013. Prior to joining Danaher, Mr. Pringle served in a series of progressively more responsible roles with Whirlpool Corporation, a manufacturer of home appliances, from 2008 until May 2012, including most recently as Senior Vice President-Integrated Business Units.
Jonathan L. Schwarz has served as Senior Vice President, Corporate Development since February 2021 and as Vice President, Strategy and Corporate Development from April 2019 to February 2021 and as Vice President, Corporate Development from July 2016 to April 2019. Prior to July 2016, Mr. Schwarz served as Vice President-Corporate Development of Danaher from 2010 to July 2016.
Edward R. Simmons has served as Senior Vice President, Strategy of Fortive since February 2021. From June 2018 to December 2020, Mr. Simmons was the President of Vista Consulting Group for Vista Equity Partners, a leading private investment firm focused on software, data, and technology-enabled businesses. In addition, from September 1999 through May 2018, Mr. Simmons served as a Partner of Bain & Company where he served as a Director in its Private Equity Practice and led its Technology, Media, and Telecommunications practice.
Peter C. Underwood has served as Senior Vice President, General Counsel of Fortive since May 2016. Prior to joining Fortive, Mr. Underwood served as Vice President, General Counsel and Secretary of Regal Beloit Corporation, a manufacturer of electric motors, from 2010 through May 2016.
Stacey A. Walker has served as a Senior Vice President, Human Resources of Fortive since July 2016. Prior to July 2016, Ms. Walker served as Vice President-Talent Management of Danaher from January 2014 to July 2016 after serving as Vice
24

Table of Contents
President-Talent Planning from December 2012 to December 2013 and as Vice President-Human Resources for Danaher’s Chemtreat business from 2008 to November 2012.
PART II
ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock has been traded on the New York Stock Exchange under the symbol FTV since July 2, 2016. As of February 19, 2021, there were approximately 2,100 holders of record of our common stock.
Issuer Purchases of Equity Securities
None.
Recent Issuances of Unregistered Securities
None.
ITEM 6. [RESERVED]
Not applicable.
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Fortive Corporation (the “Company,” “we,” “our,” and “us”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our well-known brands hold leading positions in intelligent operating solutions, precision technologies, and advanced healthcare solutions. Our businesses design, develop, service, manufacture, and market professional and engineered products, software, and services for a variety of end markets, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries across North America, Asia Pacific, Europe, and Latin America.
This MD&A is designed to provide a reader of our financial statements with a narrative from the perspective of management. Our MD&A is divided into seven sections:
Basis of Presentation
Overview
Results of Operations
Financial Instruments and Risk Management
Liquidity and Capital Resources
Critical Accounting Estimates
New Accounting Standards
BASIS OF PRESENTATION
On October 9, 2020, we completed the separation of our former Industrial Technologies segment (the “Separation”) by distributing 80.1% of the outstanding shares of Vontier Corporation (“Vontier”), the entity we created to hold the corresponding businesses, to Fortive stockholders on a pro rata basis. To effect the Separation, the Company distributed to its stockholders two shares of Vontier common stock for every five shares of the Company’s common stock outstanding held on September 25, 2020, the record date for the distribution, with the Company retaining 19.9% of the shares of Vontier common stock immediately following the Separation (the “Retained Vontier Shares”). On January 19, 2021, we completed an exchange of all of the Retained Vontier Shares as part of a non-cash debt-for-equity exchange that reduced outstanding indebtedness of Fortive by $1.1 billion.
25

Table of Contents
The accounting requirements for reporting the Separation of Vontier as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying consolidated financial statements for all periods presented reflect the results of the Vontier business as a discontinued operation. Fortive did not retain a controlling interest in Vontier and therefore the fair value of the Retained Vontier Shares and subsequent fair value changes are included in our assets of and results from continuing operations, respectively. The subsequent change in the fair value of the Retained Vontier Shares and the resulting gain will be recorded in the first quarter of 2021.
On March 7, 2018, we entered into a definitive agreement to combine four of our operating companies from our Automation & Specialty platform (the “A&S Business”) with Altra Industrial Motion Corp. (“Altra”) in a tax-efficient Reverse Morris Trust transaction. On October 1, 2018, we completed the split-off of the A&S Business and have presented the results of operations of the A&S Business in our Consolidated Statements of Earnings, and the related assets and liabilities in the Consolidated Balance Sheets as discontinued operations. These changes have been applied to all periods presented. 
Unless otherwise noted, amounts, percentages, and discussion for all periods included in Management’s Discussion and Analysis reflect the results of operations and financial condition from our continuing operations. Refer to Note 4 to our consolidated financial statements for additional information on discontinued operations.
In light of the Vontier Separation, we changed our internal reporting structure on the first day of the fourth quarter, September 26, 2020, to reflect organizational and leadership changes that allow us to better assess the operational performance of and allocate resources to our businesses. Our chief operating decision maker assesses performance and allocates resources based on our new operating segments, which are also our new reportable segments. Our new reportable segments are comprised of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. Refer to Note 19 to our consolidated financial statements for additional information about our reportable segments.
The discussion of historical information in Management’s Discussion and Analysis has been recast to reflect the new reportable segments of our continuing operations.
OVERVIEW
General
Fortive is a multinational business with global operations with approximately 47% of our sales derived from customers outside the United States in 2020. As a company with global operations, our businesses are affected by worldwide, regional, and industry-specific economic and political factors. Our geographic and industry diversity, as well as the range of products, software, and services we offer, typically help limit the impact of any one industry or the economy of any single country (except for the United States) on our operating results. Given the broad range of products manufactured, software and services provided, and geographies served, we do not use any indices other than general economic trends to predict the overall outlook for the Company. Our individual businesses monitor key competitors and customers, including their sales, to the extent possible, to gauge relative performance and the outlook for the future.
As a result of our geographic and industry diversity, we face a variety of opportunities and challenges, including technological development in most of the markets we serve, the expansion and evolution of opportunities in high-growth markets, trends and costs associated with a global labor force, and consolidation of our competitors. We define high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America, and Asia with the exception of Japan and Australia. We operate in a highly competitive business environment in most markets, and our long-term growth and profitability will depend, in particular, on our ability to expand our business across geographies and market segments, identify, consummate, and integrate appropriate acquisitions, develop innovative and differentiated new products, services, and software, expand and improve the effectiveness of our sales force, continue to reduce costs and improve operating efficiency and quality, attract relevant talent and retain, grow, and empower our talented workforce, and effectively address the demands of an increasingly regulated environment. We are making significant investments, organically and through acquisitions, to address technological change in the markets we serve and to improve our manufacturing, research and development, and customer-facing resources in order to be responsive to our customers throughout the world.
In this report, references to sales from existing businesses refers to sales from operations calculated according to generally accepted accounting principles in the United States (“GAAP”) but excluding (1) the impact from acquired businesses and purchase accounting adjustments (2) the impact of currency translation. References to sales attributable to acquisitions or acquired businesses refer to GAAP sales from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales attributable to certain divested businesses or product lines not considered discontinued operations prior to the first anniversary of the divestiture. The portion of sales attributable to the impact of currency translation is calculated as the difference between (a) the period-to-period change in sales (excluding sales impact from acquired businesses) and (b) the
26

Table of Contents
period-to-period change in sales (excluding sales impact from acquired businesses) after applying the current period foreign exchange rates to the prior year period. Sales from existing businesses should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies.
Management believes that reporting the non-GAAP financial measure of sales from existing businesses provides useful information to investors by helping identify underlying growth trends in our business and facilitating comparisons of our sales performance with our performance in prior and future periods and to our peers. We exclude the effect of acquisitions and divestiture related items because the nature, size, and number of such transactions can vary dramatically from period to period and between us and our peers. We exclude the effect of currency translation from sales from existing businesses because the impact of currency translation is not under management’s control and is subject to volatility. Management believes the exclusion of the effect of acquisitions and divestitures and currency translation may facilitate the assessment of underlying business trends and may assist in comparisons of long-term performance. References to sales volume refer to the impact of both price and unit sales.
Business Performance and Outlook
Business Performance
A novel strain of coronavirus was first identified in December 2019, and subsequently declared a pandemic by the World Health Organization in March 2020 (“COVID-19”). This outbreak has surfaced in nearly all regions around the world, resulting in governments implementing strict measures to help contain or mitigate the spread of the virus, including quarantines, “shelter in place,” and “stay at home” orders, travel restrictions, school and commercial facility closures, re-opening restrictions, among others (collectively “virus control measures”). These virus control measures have led to slowdowns or shutdowns for businesses deemed both “essential” and “non-essential” in affected areas, causing significant disruption in the financial markets both globally and in the United States, most notably during the first half of 2020. The majority of our essential production facilities around the world were open during 2020, and as of the date of this Report, all of our locations are open and operating.
Given our businesses operate globally, have diverse customers, and serve multiple end-markets, COVID-19 impacted our businesses and operating results during 2020 directly with reduced year-over-year demand from customers operating in non-essential end-markets and indirectly with reduced demand created by macroeconomic disruption or disruption in adjacent end-markets. These disruptions impacted our operating results most severely during the second quarter of 2020 and we have realized sequential improvement in demand across all of our businesses and geographies since.
For the year-ended December 31, 2020, aggregate year-over-year sales increased 1.5% as our continued application and deployment of the Fortive Business System and incremental sales from our recently acquired companies more than off-set declines in demand from our existing businesses. Sales from existing businesses decreased 5.9% during the year ended December 31, 2020 as compared to the comparable period of 2019 reflecting the broad impacts of the COVID-19 pandemic, as virus control measures were deployed in most regions and particularly impacted our results in the second quarter of 2020, with sequential improvement each quarter thereafter, including a slight year-over-year increase in demand from existing businesses during the fourth quarter.
Sales that management considers recurring revenue represented approximately 40% of our total sales during the year-ended December 31, 2020 and increased approximately 11% year-over-year, including sales from our existing software as a service (“SAAS”) businesses that increased at a rate in the mid-teens year-over-year.
Geographically, year-over-year sales from existing businesses during the year ended December 31, 2020 declined at a mid-single digit rate in both developed markets and high-growth markets, respectively, which was driven by a high-single digit rate decline in North America and Latin America, a mid-single digit rate decline in Asia, and a low-single digit rate decline in Western Europe. Year-over-year sales from existing businesses grew slightly in China during the year ended December 31, 2020.
2021 Outlook
As a result of the COVID-19 pandemic, overall global conditions have been volatile and uncertain. While our results in the fourth quarter of 2020 indicate positive, broad-based momentum across our portfolio, economic uncertainties continue to exist. The impact of the COVID-19 pandemic on our future results will depend on the length, severity, and recurrence of virus control measures and the availability of antiviral medications and distribution and administration of vaccinations, both of which are uncertain. We plan to continue deploying the Fortive Business System to help drive near-term performance and maximize cash flow generation amidst this uncertainty.
Given the diverse nature of our businesses and the end-markets they serve, we believe certain of our businesses will continue being resilient against the broad COVID-19 impacts in the first quarter of 2021, while we believe others will continue being
27

Table of Contents
relatively more sensitive, with varied rates of continued recovery as virus control measures remain in place. The businesses we believe will continue being relatively more resilient include our businesses with a greater proportion of recurring revenue, including our SAAS businesses that provide critical workflow solutions to their customers, certain healthcare businesses, and those with longer business cycles with strong backlogs. We believe our businesses that are more dependent on short-cycle industrial demand and production dynamics will continue to sequentially improve but continue experiencing a somewhat challenging environment. As such, we expect year-over-year global demand for our products and services in both the first quarter of 2021 and year ended December 31, 2021 to grow at a mid-single digit rate.
Despite the virus control measures in place in geographies critical to our supply chain, we have successfully implemented solutions to support our operations and have not experienced significant production material shortages, supply chain constraints, or distribution limitations impacting our operations as of the date of this Report; however, in light of the uncertainty of the COVID-19 pandemic severity and duration, we are continuing to evaluate and monitor the condition of our supply chain, including the financial health of our suppliers and their ability to access raw materials and other key inputs and may experience shortages, constraints, or disruptions during the first quarter of 2021 or in future periods.
We are closely monitoring the health of our employees, and continue to implement safety protocols at our facilities to help ensure their health and safety. In addition, we continue to monitor our suppliers and customers and their ability to maintain production capacity to meet our operational requirements. Individuals contracting or being exposed to COVID-19, or who are unable to report to work due to virus control measures, may significantly disrupt production throughout our supply chain and negatively impact our sales channels. Further, our customers may be directly impacted by business curtailments or weak market conditions, and may not be willing or able to accept shipments of products, may cancel orders, and may not be able to pay us on a timely basis.
To mitigate the impact of the economic conditions from the COVID-19 pandemic as well as any escalation of geopolitical uncertainties related to governmental policies toward international trade, monetary and fiscal policies, and relations between the U.S. and China, we will continue applying and deploying the Fortive Business System to actively manage our supply chain, drive operating efficiencies, and continue to collaborate with our customers and suppliers to minimize disruption to their businesses. Additionally, we will continue actively managing our working capital to maximize cash flows and cost efficiency and assess market conditions, taking actions as we deem necessary to appropriately position our businesses in light of the economic environment and geopolitical uncertainties.
While COVID-19 has created volatility and uncertainty in the financial markets, we have not experienced a significant impact on our financial position, liquidity, and ability to meet our debt covenants as of the filing date of this Report; however, we continue to monitor the financial markets and general global economic conditions. If further changes in financial markets or other areas of the economy adversely affect our access to the capital markets, we would expect to rely on a combination of available cash and existing available capacity under our credit facilities to provide short-term funding. Refer to the “Liquidity and Capital Resources” section for additional discussion.
Completed Divestitures, Acquisitions, and Business Combinations
2020
On October 9, 2020, we completed the Separation by distributing 80.1% of the outstanding shares of Vontier to our stockholders on a pro rata basis. To effect the Separation, we distributed to our stockholders two shares of Vontier common stock for every five shares of Fortive common stock outstanding held on September 25, 2020, the record date for the distribution, and retained 19.9% of the shares of Vontier common stock immediately following the Separation. The accounting requirements for reporting the Separation of Vontier as a discontinued operation were met when the Separation was completed.
On September 29, 2020, Vontier entered into a credit agreement (the “Credit Agreement”) with a syndicate of banks, consisting of a three-year, $800 million senior unsecured delayed draw term loan facility (the “Three-Year Term Loans”), a two-year, $1 billion senior unsecured delayed draw term loan facility (the “Two-Year Term Loans” and together with the Three-Year Term Loans, the “Term Loans”) and a three-year, $750 million senior unsecured multi-currency revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loans, the “Credit Facilities”). On the Distribution Date, Vontier drew down the full $1.8 billion available under the Term Loans. Vontier used the proceeds from the Term Loans to make payments to the Company, with $1.6 billion used as part of the consideration for the contribution of certain assets and liabilities to Vontier by the Company in connection with the Separation and $202 million used as an adjustment for excess cash balances remaining with Vontier (collectively, the “Cash Consideration”). The Company will apply the Cash Consideration to repay certain outstanding indebtedness, interest on certain debt instruments, and to pay certain of the Company’s regular, quarterly cash dividends. Refer to Note 11 to the consolidated financial statements for the description of the debt repayments made.
28

Table of Contents
In preparation for and executing the Separation, the Company incurred $84 million and $35 million in Vontier stand-up and separation-related transaction costs during the years ended December 31, 2020 and 2019, respectively, which have been reclassified to discontinued operations in the accompanying consolidated financial statements. These stand-up and separation-related costs primarily relate to professional and advisory fees associated with preparation of regulatory filings and separation activities within finance, tax, legal, and information system functions.
In connection with the Separation, Fortive and Vontier entered into various agreements to effect the Separation and provide a framework for Vontier’s relationship with Fortive after the Separation, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement, a Fortive Business System (“FBS”) license agreement, and a stockholder’s and registration rights agreement. These agreements govern the separation between Fortive and Vontier of the assets, employees, liabilities, and obligations (including its investments, property, and employee benefits and tax-related assets and liabilities) of Fortive and its subsidiaries attributable to periods prior to, at, and after Vontier’s separation, and also govern certain relationships between Fortive and Vontier after the Separation.
2019
Advanced Sterilization Products Acquisition
On April 1, 2019 (the “Principal Closing Date”), we acquired the Advanced Sterilization Products business (“ASP”) of Johnson & Johnson, a New Jersey corporation (“Johnson & Johnson”) for an aggregate purchase price of $2.7 billion (the “Transaction”), subject to certain post-closing adjustments set forth in a Stock and Asset Purchase Agreement, dated effective as of June 6, 2018, between the Company and Ethicon, Inc., a New Jersey corporation (“Ethicon”) and a wholly owned subsidiary of Johnson & Johnson. ASP engages in the research, development, manufacture, marketing, distribution, and sale of low-temperature terminal sterilization and high-level disinfection products.
On the Principal Closing Date, we paid $2.7 billion in cash and obtained the transferred assets and assumed liabilities in 20 countries (“Principal Countries”), general patent and trademark assignments, and all transferred equity interests in ASP. ASP has operations in an additional 39 countries (“Non-Principal Countries”). The transferred assets and liabilities associated with these operations close when requirements of country-specific agreements or regulatory approvals are satisfied.
The $2.7 billion purchase price was paid in exchange for ASP’s businesses in both Principal and Non-Principal Countries. As of December 31, 2020 we have closed 20 Principal Countries and 34 Non-Principal Countries that, in aggregate, accounted for more than 99% of the preliminary valuation of ASP. The remaining five Non-Principal Countries represent less than 1% of the preliminary valuation of ASP, or $10.1 million, which is included as a prepaid asset in Other assets in the Consolidated Balance Sheet. As each Non-Principal Country closes, we reduce the prepaid asset and record the fair value of the assets acquired and liabilities assumed. All of the provisional goodwill associated with the Transaction is included in goodwill in our Advanced Healthcare Solutions segment at December 31, 2020, and the majority of the provisional goodwill is tax deductible.
In addition, the Company entered into a transition services agreement with Johnson & Johnson for certain administrative and operational services (“TSA”) with Principal Countries and distribution agreements in the Non-Principal Countries. Under the distribution agreements, ASP sells finished goods to Ethicon at prices agreed by the parties. ASP recognizes these sales as revenue when the conditions for revenue recognition are met. Following the sale of finished goods by ASP, Ethicon obtains title of the finished goods, has full authority to sell and market the finished goods to end customers as it sees fit, and retains any revenue and profit from sale. As of December 31, 2020, ASP had exited the TSAs and substantially all of the distribution agreements. ASP expects to close the remaining Non-Principal countries in early 2021.
Other Acquisitions and Investments
In addition to the acquisition of ASP, during 2019, we acquired four businesses including Intelex Technologies and Pruftechnik, both of which complement existing businesses in our Intelligent Operation Solutions segment, and Censis Technologies within our Advanced Healthcare Solutions segment, for total consideration of $1.2 billion in cash, net of cash acquired. We recorded an aggregate of $781 million of goodwill related to these acquisitions.
Combination of the Tektronix Video Business with Telestream
On July 20, 2019, we completed the combination of the Tektronix Video test and monitoring equipment business (“Tektronix Video Business”) with Telestream, LLC (the “Combined Business”), a portfolio company of Genstar Capital LLC. We recognized a pretax gain of $41 million upon the combination, and hold a 33% equity stake in the Combined Business. This transaction did not meet the criteria for discontinued operations reporting, and therefore the operating results of the Tektronix Video Business prior to the combination with Telestream are included in continuing operations for all periods presented. Additionally, the loss from our equity investment in the Combined Business is included in Other non-operating expenses, net in
29

Table of Contents
the accompanying Consolidated Statement of Earnings. Refer to Note 4 to our consolidated financial statements for additional information.
2018
Gordian Acquisition
On July 27, 2018, we acquired TGG Ultimate Holdings, Inc. and its subsidiaries, including The Gordian Group, Inc. (“Gordian”), a privately-held, leading provider of construction cost data, software, and service, for a total purchase price of $778 million net of cash acquired (the “Gordian Acquisition”). Gordian’s comprehensive offerings serve the entire building lifecycle and provide workflow solutions designed to optimize every stage of an asset owner’s construction and maintenance needs, including connecting the owner and contractors in the same exchange and providing access to cost and facility metrics databases via a subscription-based model. We recorded $435 million of goodwill related to the Gordian Acquisition.
Accruent Acquisition
On September 6, 2018, we acquired Athena SuperHoldCo, Inc., including Accruent, LLC (“Accruent”), a privately-held, leading provider of facilities asset management software, for a total purchase price of approximately $2.0 billion net of acquired cash (the “Accruent Acquisition”). Accruent is a recognized leader in the facilities asset management industry, combining deep domain and industry capabilities with an integrated, cloud-based framework that provides insights spanning the full lifecycle of real estate, facilities, and asset management. Accruent serves over 10,000 global customers, and helps assure clients fulfill the mission of their organization by extending the lifecycle of assets, monitoring full compliance, and reducing safety risks. We recorded $1.2 billion of goodwill related to the Accruent Acquisition.
Divestiture of A&S Business
On March 7, 2018, we entered into a definitive agreement to combine four of our operating companies from our Automation & Specialty platform (the “A&S Business”) with Altra Industrial Motion Corp. (“Altra”) in a tax-efficient Reverse Morris Trust transaction. The A&S Business includes the market-leading brands of Kollmorgen, Thomson, Portescap and Jacobs Vehicle Systems, and generated approximately $900 million in revenue for the year ended December 31, 2017. On October 1, 2018, we completed the split-off of the A&S Business. The total consideration received was $2.7 billion and consisted of (i) $1.3 billion through a fully-subscribed exchange offer, in which we accepted and subsequently retired 15,824,931 shares of our own common stock from our stockholders in exchange for 35,000,000 shares of common stock of Stevens Holding Company, Inc.; (ii) $1.0 billion in cash paid to us for the direct sales of certain assets and liabilities of the A&S Business; (iii) $250 million as part of a non-cash debt-for-debt exchange that reduced outstanding indebtedness of Fortive, which is inclusive of accrued interest and fees; and (iv) $150 million in cash paid to us by Stevens Holding Company, Inc. as a dividend. The results of the A&S Business are reported as discontinued operations for all periods presented, which includes the after-tax gain on the transaction of $1.9 billion.
RESULTS OF OPERATIONS
Components of Sales Growth
 2020 vs. 20192019 vs. 2018
Total revenue growth (GAAP)1.5 %20.1 %
Existing businesses (Non-GAAP)(5.9)%(0.5)%
Acquisitions (Non-GAAP)
7.3 %22.2 %
Currency exchange rates (Non-GAAP)0.1 %(1.6)%
Refer to Intelligent Operating Solutions, Precision Technologies and Advanced Healthcare Solutions sections below for further discussion of year-over-year sales growth.
Operating Profit Margins
Operating profit margins were 11.6% for the year ended December 31, 2020, an increase of 190 basis points as compared to 9.7% in 2019. Year-over-year operating profit margin comparisons were favorably impacted by:
Operating expense savings from broad cost reduction efforts and price increases, and to a lesser extent, lower year-over-year material costs and incremental year-over-year cost savings associated with productivity improvement initiatives, which were partially offset by lower year-over-year sales volumes from existing businesses — favorable 50 basis points
30

Table of Contents
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue and inventory which were less in 2020 than the fair value adjustments recognized in 2019 — favorable 30 basis points
The year-over-year effect of acquisition-related transaction costs, as the costs related to our acquisition and integration of ASP in 2019 were greater than the costs recognized in the comparable period in 2020 — favorable 90 basis points
The year-over-year effect of amortization from existing businesses — favorable 10 basis points
The incremental year-over-year net effect of restructuring actions — favorable 10 basis points
Operating profit margins were 9.7% for the year ended December 31, 2019, a decrease of 730 basis points as compared to 17.0% in 2018. Year-over-year operating profit margin comparisons were favorably impacted by:
The year-over-year effect of amortization from existing businesses — favorable 50 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
Lower sales volumes from existing businesses, increased material costs associated primarily with inflationary pressures and recently enacted tariffs, and changes in currency exchange rates, which were partially offset by price increases and incremental year-over-year cost savings associated with productivity improvement initiatives — unfavorable 90 basis points
The incremental year-over-year net dilutive effect of acquired businesses, including amortization and acquisition-related fair value adjustments to deferred revenue and inventory — unfavorable 560 basis points
The incremental year-over-year net dilutive effect of restructuring actions — unfavorable 70 basis points
Acquisition-related transaction costs, as the costs related to our acquisition and integration of ASP in 2019 were greater than the costs associated with the ASP, Gordian, and Accruent acquisitions in 2018 — unfavorable 60 basis points
Business Segments and Geographic Area Results
Sales by business segment and geographic area for the year ended December 31 are as follows ($ in millions):
202020192018
Segments
Intelligent Operating Solutions$1,883.7 $1,898.9 $1,576.3 
Precision Technologies1,651.3 1,808.4 1,901.4 
Advanced Healthcare Solutions1,099.4 856.6 322.7 
Total$4,634.4 $4,563.9 $3,800.4 
Geographic area
United States$2,436.6 $2,394.2 $1,875.8 
China534.1 501.2 476.8 
All other (each country individually less than 5% of total sales)1,663.7 1,668.5 1,447.8 
Total$4,634.4 $4,563.9 $3,800.4 

INTELLIGENT OPERATING SOLUTIONS
Our Intelligent Operating Solutions segment provides leading solutions to accelerate industrial and facility reliability and performance, as well as compliance and safety across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others. The businesses in our Intelligent Operating Solutions segment provide a broad and differentiated offering of instrumentation, sensors, software, and services to address these critical workflows for our customers.
31

Table of Contents
Intelligent Operating Solutions Selected Financial Data
 For the Year Ended December 31
($ in millions)202020192018
Sales$1,883.7 $1,898.9 $1,576.3 
Operating profit317.8 289.0 350.3 
Depreciation28.0 40.8 38.9 
Amortization151.1 141.7 58.8 
Operating profit as a % of sales16.9 %15.2 %22.2 %
Depreciation as a % of sales1.5 %2.1 %2.5 %
Amortization as a % of sales8.0 %7.5 %3.7 %
Components of Sales Growth
2020 vs. 20192019 vs. 2018
Total revenue growth (GAAP)(0.8)%20.5 %
Existing businesses (Non-GAAP)(7.2)%1.1 %
Acquisitions (Non-GAAP)
6.4 %21.2 %
Currency exchange rates (Non-GAAP)— %(1.8)%

2020 COMPARED TO 2019
Year-over-year sales of products and services from existing businesses of Intelligent Operating Solutions declined 7.2% during the year ended December 31, 2020. The results were driven by declines in demand for portable gas detection instruments, on-premise software license and professional service offerings, and demand from our industrial channel partners, all of which were impacted by COVID-19 in both direct and adjacent end markets. Partially offsetting these declines was increased demand for our industrial imaging products and certain of our critical workflow, safety, and maintenance SAAS product offerings. Despite the year-over-year declines in demand from our industrial channel partners, we realized sequential improvement in both the third and fourth quarters of 2020 from the low point in the second quarter of 2020, and expect to return to year-over-year growth in the first quarter of 2021.
Geographically, demand from existing businesses in Intelligent Operating Solutions decreased on a year-over-year basis in both developed and high-growth markets as growth in Asia, led by Japan and China, was more than offset by declines in North America, Western Europe, and Latin America.
Price increases are reflected as a component of the change in sales from existing businesses, and year-over-year price increases in the segment contributed 1.1% to sales growth during 2020 as compared to 2019.
Operating profit margin increased 170 basis points during 2020 as compared to 2019. Year-over-year operating profit margin comparisons were favorably impacted by:
Operating expense savings from broad cost reduction efforts, price increases, lower year-over-year material costs and incremental year-over-year cost savings associated with productivity improvement initiatives, which were partially offset by lower year-over-year sales volumes from existing businesses — favorable 40 basis points
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue and inventory which were less in 2020 than the fair value adjustments recognized in 2019 — favorable 80 basis points
The year-over-year effect of acquisition-related transaction costs, as the costs related to our acquisitions in 2020 were less than the costs recognized in the comparable period in 2019 — favorable 60 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
The year-over-year dilutive effect of amortization from existing businesses — unfavorable 10 basis points
32


2019 COMPARED TO 2018
Year-over-year sales of products and services from existing businesses of Intelligent Operating Solutions grew 1.1% during 2019 as compared to 2018 as growth in demand for portable gas detection and facilities maintenance offerings was mostly offset by slowing demand from our industrial end markets in North America.
Geographically, demand from existing businesses in Intelligent Operating Solutions increased on a year-over-year basis in both developed and high-growth markets, as year-over-year growth in North America and Asia more than offset declines in Europe.
Price increases are reflected as a component of the change in sales from existing businesses, and year-over-year price increases contributed 1.9% to sales growth during 2019 as compared to 2018.
Operating profit margin decreased 700 basis points during 2019 as compared to 2018. Year-over-year operating profit margin comparisons were favorably impacted by:
Acquisition-related transaction costs, as the costs related to our acquisition of Gordian and Accruent in 2019 were less than the costs recognized in the comparable period in 2018 — favorable 90 basis points
The year-over-year effect of amortization from existing businesses — favorable 60 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
An unfavorable sales mix and lower sales volumes from existing businesses, increased material costs associated primarily with inflationary pressures and recently enacted tariffs, and changes in currency exchange rates, which were partially offset by price increases and incremental year-over-year cost savings associated with productivity improvement initiatives — unfavorable 80 basis points
The incremental year-over-year net dilutive effect of acquired businesses, including amortization and acquisition-related fair value adjustments to deferred revenue and inventory — unfavorable 700 basis points
The incremental year-over-year net dilutive net effect of restructuring actions — unfavorable 70 basis points
PRECISION TECHNOLOGIES
Our Precision Technologies segment supplies technologies to a broad set of vertical end markets, enabling our customers to accelerate the development of innovative products and solutions. We provide our customers with electrical test and measurement instruments and services, energetic material devices, and a broad portfolio of sensor and control system solutions.
Precision Technologies Selected Financial Data
 For the Year Ended December 31
($ in millions)202020192018
Sales$1,651.3 $1,808.4 $1,901.4 
Operating profit321.7 324.6 381.5 
Depreciation25.8 26.7 27.2 
Amortization17.2 20.4 22.4 
Operating profit as a % of sales19.5 %17.9 %20.1 %
Depreciation as a % of sales1.6 %1.5 %1.4 %
Amortization as a % of sales1.0 %1.1 %1.2 %
Components of Sales Growth
2020 vs. 20192019 vs. 2018
Total revenue growth (GAAP)(8.7)%(4.9)%
Existing businesses (Non-GAAP)(7.7)%(2.2)%
Acquisitions (Non-GAAP)
(1.3)%(1.5)%
Currency exchange rates (Non-GAAP)0.3 %(1.2)%



Table of Contents
2020 COMPARED TO 2019
Year-over-year sales of products and services from existing businesses of Precision Technologies declined 7.7% during 2020. The year-over-year decline in demand was largely driven by the impacts of COVID-19 in both direct and adjacent end markets, specifically for test and measurement instruments, declines in demand for sensors in the industrial end market, and a decline in shipments of our energetic materials, which was partially offset by increased demand in the medical end market for ventilator components and for critical environments supporting COVID-19 patient treatment efforts. We have realized sequential improvement in demand from the low point in the second quarter of 2020, and returned to sales growth from existing businesses in the fourth quarter of 2020. We expect to continue experiencing year-over-year growth in the first quarter of 2021.
Geographically, demand from existing businesses in Precision Technologies decreased on a year-over-year basis in both developed and high-growth markets, as growth in Latin America was more than offset by declines in North America, Asia, and Western Europe.
Price increases are reflected as a component of the change in sales from existing businesses, and year-over-year price increases contributed 1.8% to sales growth in the segment during 2020 as compared to 2019.
Operating profit margin increased 160 basis points during 2020 as compared to 2019. Year-over-year operating profit margin comparisons were favorably impacted by:
Operating expense savings from broad cost reduction efforts and price increases, and to a lesser extent lower year-over-year material costs, incremental year-over-year cost savings associated with productivity improvement initiatives, and foreign currency exchange rates, which were partially offset by lower year-over-year sales volumes from existing businesses — favorable 120 basis points
The incremental year-over-year net effect of restructuring actions — favorable 50 basis points
The year-over-year effect of amortization from existing businesses — favorable 10 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
The year-over-year net dilutive effect of the combination of the Tektronix video business with Telestream — unfavorable 20 basis points
2019 COMPARED TO 2018
Year-over-year sales of products and services from existing businesses of Precision Technologies declined 2.2% during 2019, as increased demand in our energetic materials business and for sensors in the medical end market was more than offset by declines in demand for high-performance oscilloscopes, Keithley products, electrical grid condition-based monitoring equipment, and sensing products in the industrial end market.
Geographically, demand from existing businesses in Precision Technologies decreased on a year-over-year basis in both developed and high-growth markets, as year-over-year growth in Japan was more than offset by declines in all other significant geographies.
Price increases are reflected as a component of the change in sales from existing businesses, and year-over-year price increases contributed 1.2% to sales growth during 2019 as compared to 2018.
Operating profit margin decreased 220 basis points during 2019 as compared to 2018. Year-over-year operating profit margin comparisons were unfavorably impacted by:
Lower sales volumes from existing businesses and changes in currency exchange rates, which were partially offset by price increases, a favorable sales mix, lower material costs, and incremental year-over-year cost savings associated with productivity improvement initiatives — unfavorable 70 basis points
The year-over-year net dilutive effect of the combination of the Tektronix video business with Telestream — unfavorable 40 basis points
The incremental year-over-year net dilutive effect of restructuring actions — unfavorable 110 basis points
34

Table of Contents
Advanced Healthcare Solutions Selected Financial Data
Our Advanced Healthcare Solutions segment serves healthcare customers with enabling products and services for critical activities that help ensure safe, efficient, and timely healthcare. Through the Advanced Healthcare Solutions segment, we provide broad hardware and software portfolio offerings optimized around our end-users’ most critical workflows, including instrument and device reprocessing, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation safety monitoring, and asset management.
 For the Year Ended December 31
($ in millions)202020192018
Sales$1,099.4 $856.6 $322.7 
Operating profit2.1 (72.0)5.3 
Depreciation18.1 11.4 0.5 
Amortization141.6 98.9 23.3 
Operating profit as a % of sales0.2 %(8.4)%1.6 %
Depreciation as a % of sales1.6 %1.3 %0.2 %
Amortization as a % of sales12.9 %11.5 %7.2 %
Components of Sales Growth
2020 vs. 20192019 vs. 2018
Total revenue growth (GAAP)28.3 %165.4 %
Existing businesses (Non-GAAP)0.6 %1.5 %
Acquisitions (Non-GAAP)
27.8 %166.2 %
Currency exchange rates (Non-GAAP)(0.1)%(2.3)%

2020 COMPARED TO 2019
Year-over-year sales of products and services from existing businesses of Advanced Healthcare Solutions increased 0.6% during 2020 as increased demand for cell therapy equipment design and manufacturing, radiation safety monitoring, and surgical instrument tracking SAAS products was mostly offset by a decrease in demand for consumables from our ASP business driven by a decline in elective surgical procedure volumes. Year-over-year demand for sterilization capital equipment increased slightly during 2020 as compared to 2019. Several of our Advanced Healthcare Solutions businesses are impacted by elective surgical procedure volumes, and year-over-year, elective surgical procedure volumes declined at a high-single digit rate across most major geographic markets, at rates that varied throughout the year based on COVID-19 patient hospitalizations and virus control measures in place. We expect surgical procedure volumes to improve when COVID-19 patient hospitalizations are lower and virus control measures ease.
Geographically, demand from existing businesses in Advanced Healthcare Solutions increased in developed markets and decreased in high-growth markets, as growth in Western Europe and China was more than offset by declines in North America, the Middle East, and Japan.
Price increases are reflected as a component of the change in sales from existing businesses, and year-over-year price increases contributed 0.8% to sales growth during 2020 as compared to 2019.
Operating profit margin increased 860 basis points during 2020 as compared to 2019. Year-over-year operating profit margin comparisons were favorably impacted by:
Operating expense savings from broad cost reduction efforts and price increases, and to a lesser extent, lower year-over-year material costs, incremental year-over-year cost savings associated with productivity improvement initiatives, and foreign currency exchange rates, that more than offset lower year-over-year sales volumes from existing businesses and an unfavorable sales mix — favorable 40 basis points
The year-over-year effect of amortization from existing businesses – favorable 250 basis points
The incremental year-over-year effect of acquired businesses, including amortization and acquisition-related fair value adjustments to deferred revenue and inventory which were less in 2020 than in 2019 — favorable 160 basis points
35

Table of Contents
Acquisition-related transaction costs, as the costs related to our acquisition and integration of ASP and Censis in 2020 were less than the costs recognized in the comparable period in 2019 — favorable 450 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
The incremental year-over-year net dilutive effect of restructuring actions — unfavorable 40 basis points
2019 COMPARED TO 2018
Year-over-year sales of products and services from existing businesses of Advanced Healthcare Solutions increased 1.5% during 2019 as compared to 2018, as increased demand for radiation safety monitoring was partially offset by declines in cell therapy equipment design and manufacturing.
Geographically, demand from existing businesses in Advanced Health Solutions increased on a year-over-year basis in both developed and high-growth markets, as year-over-year growth in North America and Asia was partially offset declines in Europe.